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Significant advances have been made in thyroid can-
cer research in recent years, therefore relevant clinical 
guidelines need to be updated. The current Polish 
guidelines “Diagnostics and Treatment of Thyroid 
Carcinoma” have been formulated at the “Thyroid 
Cancer and Other Malignancies of Endocrine Glands” 
conference held in Wisła in November 2015 [1]. 
The Chair of the Scientific Committee, Professor Bar-
bara Jarzab, invited all scientific societies engaged in 
clinical management of thyroid carcinoma to delegate 
their official representatives to participate as authors in 
updating these guidelines. In response, the following 
scientific societies prepared and accepted the updated 
guidelines: the Polish Endocrine Society, Polish Society 
of Oncology, Polish Thyroid Association, Polish Soci-
ety of Pathologists, Society of Polish Surgeons, Polish 
Society of Surgical Oncology, Polish Society of Clinical 
Oncology, Polish Society of Radiation Oncology, Polish 
Society of Nuclear Medicine, Polish Society of Paediatric 
Endocrinology, Polish Society of Paediatric Surgeons, 
and the Polish Society of Ultrasonography.
The Guidelines, prepared in a short time, were pub-
lished in January 2016 by the Polish Journal of Endo-
crinology. However, in several instances, not only their 
style and clarity asked for improvement, but also new 
developments and new evidence-based medical data 
required reflection and modification of some of the rec-
ommended procedures. Thus the need arose to update 
the entire content of these guidelines [1]. 
At the initiative of Professor Andrzej Lewinski, National 
Consultant in Endocrinology and President of the Polish 
Thyroid Association, the Thyroid Cancer Guidelines 
Group was formed in January 2017. This group, which 
included Professor Marek Ruchała, President of the 
Polish Endocrine Society, and Professor Barbara Jarząb, 
President of the Polish Group for Endocrine Tumours 
(PGNE), authorised Professor Marek Dedecjus, Presi-
dent of the Polish Society of Organ Biopsy, to invite as 
co-authors recognised authorities in their relevant 
disciplines, to collaborate in updating these guidelines. 
The list of these experts as co-authors was approved by 
the whole collaborating group.
The Authors Group met in Warsaw on April 26, 2017. 
At this meeting recommendations were selected which 
urgently required correction and updating and recom-
mendations that would be updated in the future (the 
next updating round being foreseen in 2018). Profes-
sor Dedecjus led this discussion and later continued it 
on-line, recording all changes proposed. At the same 
meeting it was decided to supply the Polish recom-
mendations with medical justification, in line with the 
Evidence-Based Medicine (EBM) approach [2]. This task 
was assigned to Professor Barbara Jarzab, who within 
her team of collaborators found a group of co-authors 
for this work. This group of co-authors consisted of the 
following experts: Daria Handkiewicz-Junak, Agnieszka 
Czarniecka, Agata Bałdys-Waligórska, Ewa Chmie-
lik, Jolanta Krajewska, Dagmara Rusinek, Małgorzata 
Oczko-Wojciechowska, Beata Jurecka-Lubieniecka, 
Tomasz Gawlik, Kornelia Hasse-Lazar, Michał Kalemba, 
Agnieszka Kotecka-Blicharz, Aleksandra Kropińska, 
Aleksandra Kukulska, Aleksandra Ledwon, Barbara 
Michalik, Tomasz Olczyk, Ewa Paliczka-Cieślik, Zbig-
niew Puch, Józef Roskosz, Aleksandra Syguła, Sylwia 
Szpak-Ulczok, Zbigniew Wygoda, Emilia Kulik, Elżbieta 
Lewandowska-Jabłońska, and Ewa Zembala-Nożyńska.
It was decided to base the Polish recommendations on 
the ADAPTE system [3] used by the European Thyroid 
Association (ETA) in their documents published over 
the years 2013–2017 [2, 3]. Within this system, each 
recommendation is evaluated according to its strength 
(Strength of Recommendation; SoR) — within grades 
G1; or G2; (Table I), and an additional grade to evaluate 
the quality of its supporting medical evidence. Thus, the 
ETA applies two evaluation criteria, with additional sub-
divisions (cf. Table I). Within the Quality of Evidence 
(QoE) criterion, we have added a third, lowest, grade if 
our recommendation is based on the Polish consensus 
— it is then labelled QoE: PolCon.
We have also strived to supply each recommendation 
with a reference to relevant literature, if available. 
References were taken from a set of publications 
gathered by ATA experts [4] who applied EBM rules 
in their selection. If the recommendation relevant to 
the Polish conditions is covered by the recommenda-
tions published by ATA, we quote the number of the 
relevant ATA recommendation. For example, ATA 
GL R5 indicates that the subject is dealt with in ATA 
recommendation number five (R5). Those interested 
should refer to the ATA recommendations [4] and ATA 
36
Guidelines of Polish National Societies Diagnostics and Treatment of Thyroid Carcinoma 2018 Update Barbara Jarząb et al.
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
recommendations referring to medullary thyroid cancer 
(ATA GL MTC) [6]. 
We also wish to remind the reader that the Polish rec-
ommendations established in November 2015 were de-
veloped as a consensus based on the earlier-published 
Recommendations of the American Thyroid Association 
(ATA). These meticulously prepared recommendations 
(ATA GL) contained full references to published medical 
evidence. At the time, the Polish experts believed that 
reliance on ATA recommendations would be sufficient, 
but a consensus should be reached as to which of these 
recommendations would apply in the Polish conditions. 
In our current update of the Polish recommendations 
we were, however, aware that any oncological recom-
mendations must be based on medical evidence. In the 
currently published Update of these Recommendations 
we were able to extend our 2016 Recommendations 
by adding the relevant medical evidence. We are also 
aware that future work on the Polish Recommendations 
will enable further, more accurate medical evidence 
relevant to the Polish conditions, to be included. 
I. Diagnostics of thyroid cancer
1. Indications for thyroid ultrasound [5]:
1.1. Nodular goitre or palpable thyroid nodule
 SoR: G1; QoE: +++; ATA GL R6
1.2. Neck lymph node enlargement not related to 
infection. SoR: G1; QoE: PolCon 62/62
1.3. Thyroid enlargement without any palpable 
tumour.
 SoR: G1; QoE: PolCon 62/62
1.4. Thyroid lesion detected by ultrasonography 
performed due to other reasons or by other 
imaging tools.
 SoR: G1; QoE: +++; ATA GL R6
1.5. RET germline mutation carriage and/or high 
serum calcitonin (Ct) concentration [6].
 SoR: G1; QoE: +++; ATA GL MTC
1.6. History of exposure to previous neck radiation [7].
 SoR: G1; QoE: +++
1.7. Other suspicion of thyroid disease.
 SoR: G1; QoE: PolCon 62/62
1.8. Neck ultrasound is not a screening tool [8].
 SoR: G2; QoE: PolCon 62/62
1.9. There is no sufficient evidence to recommend or 
not to recommend screening neck ultrasound in 
persons with a risk of familiar differentiated thy-
roid cancer (DTC) arising from the follicular cell.
 SoR: G2; QoE: PolCon 62/62
1.10. Neck ultrasound together with physical ex-
amination is sufficient to exclude nodular goitre.
 SoR: G1; QoE: PolCon 62/62
2. Other useful diagnostic examinations in nodular 
goitre include:
2.1. In every case of nodular goitre: TSH. If TSH is 
abnormal, assessment of serum fT4 or fT4/fT3 
is recommended [4].
 SoR: G1; QoE: ++; ATA GL R2
2.2. Anti-thyroid peroxidase antibodies (TPOAb) 
and other anti-thyroid antibodies, depending 
on experience of the particular centre.
 SoR: G2; QoE: PolCon 61/62
2.3. Assessment of serum calcitonin (Ct) concentra-
tion is useful in diagnostics of nodular goitre, 
but it is not recommended in every case, due 
to low risk of medullary thyroid cancer (MTC). 
However, Ct assessment is useful [6]:
 SoR: G2; QoE: ++; PolCon 62/62; ATA GL 4
2.3.1. If there is clinical suspicion of MTC, and in RET 
mutation carriers [6].
 SoR: G1; QoE: +++
Table I. Evidence-Based Medicine (EBM) system evaluating the strength of a recommendation [2, 3] (modified)
Strength of Recommendation (SoR) Clinical Interpretation
G1 Strong recommendation (for or against) concerns all 
patients in most clinical conditions. Abiding by this 
recommendation is evidently advantageous to the patient
This recommendation may be applied without any doubt. It will benefit 
most patients in practically all cases
G2 Weak recommendation (for or against); an optimal 
management may differ depending on the epidemiology 
or on the patient’s clinical workout. Application of this 
recommendation is to be decided by the acting clinician
This grade of a recommendation requires that analysis be performed by the 
acting clinician whether the patient is likely to benefit from its application. In 
this analysis the quality of supporting medical data needs to be considered 
as well as the patient’s condition. The acting clinician should also correctly 
appraise his or her competence to apply this recommendation
Quality of evidences (QoE)
+++ High quality data obtained from randomized clinical trials (RCT) or from unequivocal results of retrospective analyses directly concerning 
the subject of recommendation
++ Moderate quality data obtained from studies judged by the EBM approach to be methodologically deficient or the conclusions of which 
are equivocal or indirect
+ Low quality data based on case studies or on clinical observations only
PolCon Lack of direct data with regard to the conditions in Poland. The statement is based on a consensus reached via discussion among Polish 
experts (the number of Polish experts in support of this statement is given in parentheses)
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2.3.2. To exclude MTC prior to planned thyroid sur-
gery (see par. 3.3.1).
 SoR: G2; QoE: PolCon 62/62
2.4. Assessment of serum thyroglobulin (Tg) is 
not recommended, as it provides no essen-
tial information on suspected malignancy in 
a thyroid lesion.
 SoR: G1; QoE: ++; ATA GL R3 and R34
2.5.  99mTc thyroid scan is recommended only if TSH 
is close to, or below the lower limit of normal 
range, in a patient with nodular goitre [9].
 SoR: G2; QoE: ++
2.6. Elastography is not routinely required in the 
assessment of thyroid lesions; however, it may 
be helpful in the selection of a thyroid lesion 
amendable to fine-needle aspiration biopsy 
(FNAB) [10–12].
 SoR: G2; QoE: PolCon 62/62
2.7. MRI and CT are not routinely used in the 
evaluation of thyroid nodules [9].
 SoR: G1; QoE: PolCon 62/62
2.8. FDG-PET-CT is not recommended in differen-
tial diagnostics of thyroid nodules [9].
 SoR: G1; QoE: +; ATA GL R5 and R18
3. Features of increased malignancy risk in a thyroid 
lesion, evaluated prior to FNAB:
3.1. Clinical
3.1.1. Lymph node and/or distant metastases 
(see par. 11.2) [8].
 SoR: G1; QoE: ++; ATA GL R9-R8
3.1.2. History of previous neck exposure to 
radiation [7].
 SoR: G1; QoE: +++; ATA GL R2 and R20
3.1.3. History of familial thyroid cancer (it 
concerns MTC) [8].
 SoR: G2; QoE: +; ATA GL R1
3.1.4. Clear tumour growth. Note that benign 
lesions may grow at the same rate [5–8].
 SoR: G1; QoE: PolCon 62/62
 IMPORTANT NOTICE: Rapid lesion 
enlargement (within a few weeks) may 
strongly suggest anaplastic thyroid cancer, 
requiring urgent consultation by an oncol-
ogist and/or oncological endocrinologist.
 SoR: G1; QoE: PolCon 62/62
3.1.5. Hard nodule attached to neighbouring 
tissues.
 SoR: G1; QoE: +
3.1.6. Tumour over 4 cm in diameter.
 SoR: G1; QoE: + / PolCon 62/62; ATA GL R20
3.1.7. Nodule occurrence before 20 years of age.
 SoR: G1; QoE: + / PolCon 62/62
3.1.8. Nodule occurrence after 60 years of age.
 SoR: G1; QoE: + / PolCon 62/62
3.1.9. Paresis of recurrent laryngeal nerves, 
particularly unilateral.
 SoR: G1; QoE: + / PolCon 62/62
3.2. Sonographic [5]:
3.2.1. Sonographic features suggesting prob-
ability of thyroid cancer metastases 
to cervical lymph nodes (see also par. 
11.2.2) [1, 9].
  SoR: G1; QoE: +++
3.2.2. Thyroid capsule infiltration with or 
without infiltration of adjacent neck 
structures.
 SoR: G1; QoE: ++
3.2.3. Microcalcifications inside the thyroid 
lesion.
 SoR: G1; QoE: +++ / PolCon 62/62
3.2.4. Solid, hypoechoic tumour pattern.
 SoR: G1; QoE: +++
3.2.5. Tumour shape (taller than wider).
 SoR: G1; QoE: + / PolCon 62/62
3.2.6. Irregular tumour margins.
 SoR: G1; QoE: + / PolCon 62/62
3.2.7. Increased tumour vascularisation.
 SoR: G1; QoE: +
 IMPORTANT NOTICE! Sonographic 
appearance of follicular neoplasms, 
including thyroid carcinoma, often 
does not present the above-mentioned 
sonographic risk features — lesions have 
regular margins, they could be isoechoic 
without microcalcifications.
 SoR: G1; QoE: +
4. Indications for FNAB of a thyroid lesion:
4.1. Thyroid lesion ≥ 1 cm in at least one dimen-
sion and ≥ 5 mm in other dimensions, if 
there are no other lesions showing a higher 
risk of malignancy (evaluated according to 
rules given in par. 3), which require FNAB 
first — see par. 5 concerning multiple thyroid 
lesions.
 SoR: G1; QoE: PolCon 62/62; ATA GL R7 and 
R8
4.2. A thyroid lesion below 1 cm in the greatest di-
mension if clinical or sonography risk features 
of malignancy are present and reliable FNAB 
is possible.
 SoR: G1; QoE: PolCon 62/62; ATA GL R8
4.2.1. Sonography follow-up of a thyroid le-
sion below 1 cm in the greatest dimen-
sion every 3–6 months, depending on 
clinical risk, and postponement of FNAB 
until tumour diameter reaches 1 cm, is 
acceptable.
 SoR: G1; QoE: PolCon 62/62; ATA GL R8
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4.3. Thyroid lesions, regardless of their diameter, if 
lymph node or distant metastases from thyroid 
cancer, high calcitonin concentration or RET 
mutation carriage are present if reliable FNAB 
is possible.
 SoR: G1; QoE: PolCon 62/62
5. Indications for FNAB in multifocal thyroid lesions [9]:
5.1. The risk of thyroid cancer in a patient with 
multifocal thyroid lesions and a single thyroid 
lesion are comparable [8].
 SoR: G1; QoE: +++; ATA GL R21
5.2. The optimal strategy assumes selection of 
thyroid lesions for FNAB depending on their 
malignancy risk (lesions presenting the highest 
risk features should undergo biopsy first) and 
carrying out biopsy in all lesions in which it is 
indicated, or in at least four lesions with the 
highest clinical and sonography risk features.
 SoR: G1; QoE: ++/PolCon 62/62
5.3. If a negative FNAB result is obtained in all 
lesions, selected as above, exclusion of malig-
nancy risk may be considered with reasonable 
probability. In cases of sequential biopsy proce-
dures all above-determined biopsy sites should 
be investigated within the following 3–6-month 
period, depending on risk assessment.
 SoR: G1; QoE: + / PolCon 62/62
5.4. If thyroid lesions are multiple, they have 
a similar sonographic pattern and do not pre-
sent significant features of malignancy, FNAB 
of the biggest lesion only is acceptable [5].
 SoR: G1; QoE: + / PolCon 62/62
5.5. If diffuse changes in thyroid echostructure 
are present, indications for FNAB are relative 
and FNAB may be taken only from a single 
localisation. In such cases the National Can-
cer Institute (NCI) accepts biopsy without 
sonography guidance, particularly if thyroid 
is clearly enlarged [9].
 SoR: G1; QoE: + / PolCon 62/62
5.6. Elastography may be helpful in the selection 
of a lesion for FNAB; however, it is not obliga-
tory [10–14]
 SoR: G1; QoE: PolCon 62/62
6. Indications for FNAB after diagnosis of thyroid le-
sion by other imaging modalities.
6.1. Thyroid lesions, incidentally detected in ul-
trasound performed for other reasons (such 
as Doppler ultrasound of carotid arteries), are 
subject to rules given in par. 3, 4, and 5.
 SoR: G1; QoE: ++ / PolCon 62/62
6.2. Thyroid lesions, detected by CT or MRI, should 
be initially evaluated by ultrasound. Further 
management depends on the result of this 
ultrasound examination, subject to rules given 
in par. 3, 4, and 5.
 SoR: G1; QoE: ++
6.3. Hot lesions, detected by FDG-PET, should 
be initially evaluated by ultrasound. Further 
management depends on the result of this ul-
trasound examination, subject to rules given in 
par. 3, 4, and 5. However, FNAB of a hot thyroid 
lesion on FDG-PET is obligatory [15, 16].
 SoR: G1; QoE: + / PolCon 62/62 ATA GL R5
6.4. Hot lesions, detected incidentally by 99mTcMIBI 
(a heart scan), should be initially evaluated by 
ultrasound. Further management depends 
on the result of this ultrasound examination, 
subject to rules given in par. 3, 4, and 5.
 SoR: G1; QoE: ++ / PolCon 62/62
7. FNAB of a thyroid lesion is not advised:
7.1. In lesions less than 5 mm in all diameters FNAB 
is not routinely recommended due to low clini-
cal risk with exceptions given in par. 4.3.
 SoR: G1; QoE: PolCon 62/62
7.2. In pure cystic lesions, according to sonography 
criteria.
 SoR: G1; QoE: ++; ATA GL R8
7.3. In lesions showing spongiform appearance on 
ultrasound in at least 50% of the lesion volume.
 SoR: G2; QoE: + / PolCon 62/62; ATA GL R8
7.4. In lesions that appear as autonomous on the 
thyroid scan (so-called “hot nodule”) [9].
 SoR: G2; QoE: ++; ATA GL 22
8. Cytological classification of lesions subjected to 
FNAB should be based on NCI guidelines, referred 
to the Bethesda System for Reporting Thyroid Cyto-
pathology called “Bethesda Classification” in these 
“Recommendations” (Table II) [17, 18].
 SoR: G1; QoE: ++ / PolCon 62/62; ATA GL R9
9. FNAB — execution and technique.
9.1. Requirements for ultrasound-guided FNAB 
[5, 9].
 SoR: G1; QoE: PolCon 62/62; ATA GL R8 and R10
9.1.1. Concerning all FNAB procedures [5].
 SoR: G1; QoE: PolCon 62/62; ATA GL R6
9.1.2. Ultrasound-guidance is recommended 
during biopsy of any thyroid lesion. It 
is not required in general thyroid en-
largement with diffuse echostructure 
alterations with no clear lesions.
 SoR: G1; QoE: PolCon 62/62
9.1.3. Ultrasound-guided FNAB is always re-
quired if FNAB is repeated due previous 
non-diagnostic result [4, 5].
 SoR: G1; QoE: PolCon 62/62; ATA GL R10
9.2. Written, informed consent is always required.
 SoR: G1; QoE: PolCon 62/62
39
Endokrynologia Polska 2018; 69 (1)
SZ
K
O
LE
N
IE
 
PO
D
YP
LO
M
O
W
E
10. Information, which should be provided in the re-
ferral form.
10.1. First name, last name, and address of the refer-
ring physician.
10.2. First name, last name of the patient or patient’s 
identification number.
10.3. Patient’s sex and age.
10.4. Initial clinical diagnosis.
10.5. Lesion location and diameter.
10.6. Data related to patient history (any primary 
cancer, exposure to neck irradiation, concomi-
tant thyroid disorders).
10.7. Information related to administered treatment, 
if relevant to interpretation of cytological 
results.
10.8. Data about any previous FNAB (date, lesion 
location, diagnosis).
 SoR: G1; QoE: PolCon 62/62
Table II. The 2017 Bethesda System for Reporting Thyroid Cytopathology [17, 18]
Category Recommended 
terminology
Risk of  
malignancy
Risk of malignancy 
considering NIFTP  
as postoperative 
outcome
The risk of  
malignancy  
in Polish  
patients
Cytological diagnoses included in 
a particular category and other 
comments
I Nondiagnostic 
or  
unsatisfactory
5–10 5–10 5–10%* Clinical context should be considered
II Benign 0–3 0–3 < 1%* Nodular goitre 
Thyroiditis, including chronic 
inflammations 
Hyperplastic nodule 
Colloid nodule (lots of colloid, sufficient 
cellularity) 
Cytological findings suggest colloid nodule 
(lots of colloid, insufficient cellularity) 
Thyroid cyst
III Atypia of 
undetermined 
significance 
(AUS) 
or Follicular 
lesion of 
undetermined 
significance
~10–30 6–18 2.4–5.2% This category should be used in rare 
cases when it is not possible to state a 
precise cytological diagnosis
IV Follicular 
neoplasm  
or  
Suspicious 
for a follicular 
neoplasm
25–40 10–40 8.2–19% At least 25% of lesions belonging to 
this category are not neoplastic tumors 
(hyperplastic nodules, inflammation). 
This category should not be diagnosed 
when nuclear features of papillare thyroid 
cancer are present
V Suspicious for 
malignancy
50–75 45–60 75% This category involves: 
— papillary thyroid cancer 
— medullary thyroid cancer 
— lymphoma 
— metastatic carcinoma 
— anaplastic thyroid cancer/vascular 
sarcoma due to the presence of necrotic 
tissues 
VI Malignant 97–99 94–96 95–100%* This category involves: 
— papillary thyroid cancer 
— medullary thyroid cancer 
— lymphoma 
— metastatic carcinoma 
— anaplastic thyroid cancer/ vascular 
sarcoma
*lack of Polish data — data given in the table are NCI data
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11. Selection of lesion for FNAB: 
11.1. The selection of the lesion for FNAB is based 
on ultrasound according to the following rules 
[8, 9].
11.1.1. The main criterion is not lesion diameter 
but the presence of clinical and sono-
graphic features of malignancy risk [9]. 
 SoR: G1; QoE: +++; ATA GL R8
11.1.2. A large nodule requires several biopsies 
taken from different locations within the 
nodule [19].
 SoR: G1; QoE: + / PolCon 62/62; ATA GL R
11.1.3. A cyst should be drained. If any of its 
solid part is present, FNAB is required. 
The liquid obtained by FNAB may un-
dergo centrifuging and precipitation to 
prepare a smear [5].
 SoR: G1; QoE: PolCon 62/62
11.2. In the case of neck lymph node enlargement [5].
11.2.1. If a thyroid nodule is accompanied by 
the presence of a suspicious lymph 
node, the lymph node should also un-
dergo FNAB.
 SoR: G1; QoE: ++
11.2.2. Sonography features of suspected meta-
static lymph node are: transversal diam-
eter greater than 5 mm, loss of hilar ar-
chitecture, heterogenic echotexture with 
cystic areas, round shape, peripheral or 
mixed vascularity, microcalcifications [9].
 SoR: G1; QoE: +++
12. Representativeness of FNAB.
12.1. Qualitative and quantitative assessment of the 
representativeness of a cytological aspirate is 
obligatory [17].
 SoR: G1; QoE: PolCon 62/62
12.2. Qualitative evaluation is expressed dichoto-
mously as satisfactory or unsatisfactory and 
should consider the differences related to le-
sion type (see par. 13.1) [17].
 SoR: G1; QoE: PolCon 62/62
12.3. The following grading of quantitative assess-
ment is recommended:
12.3.1. Diagnostic material: at least five groups 
of cells containing at least 10 well-
preserved follicular cells. It is necessary 
to consider the clinical context when 
preparing this assessment.
 SoR: G1; QoE: PolCon 62/62
12.3.2. Diagnostic material, in spite of its poor 
cellularity (see par. 14.1).
 SoR: G1; QoE: PolCon 62/62
12.3.3. Non-diagnostic material, due to lack of, 
or small number of follicular cells.
 SoR: G1; QoE: PolCon 62/62
12.3.4. Cyst liquid only.
 SoR: G1; QoE: ++ 
13. Qualitative assessment of FNAB — clinical and 
radiological aspects [20].
13.1. Solid thyroid nodules.
13.1.1. With cytological cellular features indi-
cating suspicion of malignancy (cellular 
atypia), a variant of Bethesda, class III 
category. Diagnosis of cells suspected of 
malignancy in a cytological smear must 
be given in the final FNAB report, even 
if the number of cells is small (see point 
12.3.2, 14.3.4.2.) [20].
 SoR: G1; QoE: + / PolCon 62/62
13.1.2. With inflammation [17, 19].
 In this case the aspirate may contain 
fewer follicular cells; therefore, fulfill-
ing the criterion of par. 12.3.1 is not 
absolutely crucial. The criterion given in 
point 12.3.2 should then be considered.
 SoR: G2; QoE: + 
13.1.3. With large colloid amount.
 The presence of a large colloid amount 
is a reliable proof of a tumour being 
benign, so FNAB may be diagnostic 
despite its poor cellularity [17].
 SoR: G2; QoE: + / PolCon 62/62
13.1.4. With follicular hypertrophy and small 
colloid amount.
 Criterion 12.3.1 is optimal, particularly 
if fulfilled in one smear. However, ex-
cessively restrictive requirements re-
garding sample cellularity and quality 
may increase the percentage of non-
diagnostic FNABs to 20% or higher [17].
 SoR: G1; QoE: PolCon 62/62
13.2. Cysts.
13.2.1. Pure cyst (sonography criterion): the 
risk of cancer 1–4% [5, 9].
 Aspiration of a pure cyst very rarely 
involves cancer diagnosis. The use of 
criterion 12.3.4 makes a clinically useful 
report possible. Adding the description 
“non-diagnostic material to fully exclude 
appearance of cystic cancer” may be 
considered.
 SoR: G1; QoE: +
13.2.2. According to this consensus, in such 
cases FNAB of the solid part of the 
nodule should be performed.
 SoR: G1; QoE: PolCon 62/62
14. Recommended diagnostic terminology.
 It is recommended that six classes of cytological 
diagnosis be used, according to the Bethesda Clas-
sification [18, 20].
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14.1. Non-diagnostic FNAB (Bethesda class I).
14.1.1. The FNAB result is defined as non-diag-
nostic if it does not fulfil representative-
ness criteria (see par. 12), considering the 
clinical-radiological context (see par. 13).
 SoR: G1; QoE: PolCon 62/62; ATA GL R9
14.1.2. Non-diagnostic FNAB may be related to 
three causes [5]:
14.1.2.1. Inadequate cellularity.
14.1.2.3. Lack of follicular cells.
14.1.2.3. Incorrect sample fixation and 
storage.
SoR: G1; QoE: ++
14.2. Benign nodule (Bethesda class II).
 This term represents final diagnosis of nodular 
goitre, thyroiditis (acute, subacute, and auto-
immune), a single hyperplastic, or a colloid 
nodule. The risk of malignancy is minimal 
[18, 21]. See also par. 24.2.2.
 SoR: G1; QoE: +++
14.2.1. The diagnosis of a “benign nodule” 
formally involves also the diagnosis 
of follicular adenoma; therefore, some 
centres apply the statement “FNAB 
negative with reference to malignancy” 
or “non-malignant lesion”. The guide-
lines recommend the statement “benign 
lesion” in such a case. 
 SoR: G1; QoE: PolCon 62/62
14.2.2. FNAB smear should contain an ad-
equate number of cells. If the number 
of cells is too small and a repeated 
FNAB shows mainly colloid and also 
few cells, the appearance of which does 
not suggest malignancy, the diagnosis 
“cytological picture suggests a colloid 
lesion/nodule” is recommended.
 SoR: G1; QoE: PolCon 62/62
14.3. Follicular lesion of undetermined significance 
(Bethesda class III) [22, 23].
14.3.1. This diagnosis should be stated as rarely 
as possible [17].
 SoR: G1; QoE: PolCon 62/62
14.3.2. This diagnostic category may be stated 
after exclusion of the five remaining 
Bethesda classes, to represent cytologi-
cal findings that fulfil neither qualita-
tively nor quantitatively the “suspicious 
for a follicular neoplasm” or “suspicious 
for malignancy” criteria.
 SoR: G2; QoE: + / PolCon 62/62
14.3.3. Qualification of Bethesda class III may 
be related to sample limitations (low 
cellularity, blood admixture, incorrect 
fixation), if cellular features do not un-
equivocally indicate their benign char-
acter or even if malignancy is suspected. 
Pathologist’s comment is necessary.
 SoR: G1; QoE: PolCon 62/62
14.3.4. In many centres this category is divided 
to two subcategories [4, 17]:
14.3.4.1 The first one is a “follicular 
lesion of undetermined signifi-
cance — FLUS” — these lesions 
are characterised by a highly 
cellular smear, the presence of 
rosette architecture, variability 
of eosinophilic cytoplasm, and 
paucity of colloid.
 SoR: G2; QoE: + / PolCon 62/62; 
ATA GL R15
14.3.4.2 The second subcategory is 
“Atypia of undetermined signifi-
cance — AUS” — strong nuclear 
polymorphism, nuclear hetero-
chromia, single grooves and nu-
clear clearances, macronucleosis 
in lesions, which have been 
not subjected to any previous 
therapy. The AUS subcategory 
indicates risk of malignancy 
at least two-times higher than 
that of the FLUS subcategory 
and mainly concerns thyroid 
cells with features suggesting 
papillary thyroid cancer (PTC).
 SoR: G2; QoE: + / PolCon 
62/62; ATA GL R15
14.3.5. The criteria that differentiate between 
categories “follicular lesion of undeter-
mined significance” and “suspicious 
for a follicular neoplasm” are given in 
Table III. 
 According to Polish data, the risk of 
malignancy in follicular lesions of un-
determined significance ranges between 
2.4% and 5.2% [22–24]. So far, the vast 
majority of such lesions in Poland were 
benign nodules or follicular neoplasms 
demonstrating low risk of malignancy. 
Thereby, according to the authors 
of these guidelines the diagnosis of 
a follicular lesion of undetermined 
significance should not constitute in 
itself an indication for surgery. It has 
not yet been proven in Poland that this 
diagnosis significantly increases the risk 
of malignancy compared with benign 
nodules [21, 23, 25].
 SoR: G2; QoE: + / PolCon 62/62
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14.3.6. If Bethesda III category is stated on the 
basis of abnormalities in a cell structure, 
a higher risk of malignancy has to be 
considered.
 SoR: G2; QoE: PolCon 62/62
14.3.7. Particular caution in interpretation is 
required in diagnosis of a follicular le-
sion of undetermined significance in 
small lesions not exceeding 1 cm in any 
dimension.
 SoR: G2; QoE: PolCon 62/62
14.3.8. Follicular lesion of undetermined signif-
icance constitutes a substitute diagnosis 
that requires further correction, in cor-
relation with clinical and sonographic 
features of the lesion during the next 
FNAB (see par. 25).
 SoR: G2; QoE: PolCon 62/62
14.4. Suspicious for follicular neoplasm (Bethesda 
class IV) [25, 26].
14.4.1. NCI recommends the statement “Suspi-
cious for follicular neoplasm” because 
25% of these nodules are not in fact 
neoplasms [17]. Diagnostic criteria are 
given in Table III.
 SoR: G1; QoE: ++
14.4.2. This class involves lesions previously 
known as either “follicular/oncocytic 
neoplasm” or “follicular/oncocytic tu-
mour”. It should not involve lesions 
that show nuclear features of papillary 
thyroid cancer (see par. 14.4.8).
 SoR: G2; QoE: PolCon 62/62
14.4.3. “Suspicious for a Hurthle-cell neoplasm” 
(previously “suspicious for a oncocytic/
oxyphilic neoplasm”; see also par. 14.4.8).
 SoR: G2; QoE: PolCon 62/62
14.4.4. The risk of malignancy of a lesion “sus-
picious for a follicular neoplasm” in Po-
land is 8.2–19% [21, 25, 26] and depends 
on the centre. Therefore, the decision 
concerning surgery may be made with 
reference to the centre’s experience.
 SoR: G2; QoE: PolCon 62/62
14.4.5. The diagnosis of “suspicious for a fol-
licular neoplasm” should be stated in 
cases when the pathologist anticipates 
the necessity of surgery and final histo-
pathological diagnosis [17, 25].
 SoR: G1; QoE: +++
14.4.6. Considering this diagnosis, the risk of 
cancer should be evaluated individually 
together with clinical-epidemiological 
factors [20, 26].
 SoR: G2; QoE: PolCon 62/62
14.4.7. If the diagnosis “suspicious for a fol-
licular neoplasm” is an indication for 
surgery it should be confirmed by an-
other pathologist.
 SoR: G2; QoE: PolCon 62/62
14.4.8. This statement may reflect a final his-
topathological diagnosis of a follicular 
adenoma, follicular carcinoma, and 
follicular variant of papillary thyroid 
carcinoma, and their oxyphilic variants. 
However, it may also indicate a non-
Table III. Cytologic criteria for diagnosis of „follicular lesion of undetermined significance” „suspicion for a follicular neoplasm”
Feature Follicular lesion of undetermined 
significance
Suspicious for a follicular  
neoplasm
Hypercellular aspirate (subjective) Rather yes Yes
Prominent population of small arrangement 
(groups, nests, rosets)
Yes Yes
Sheets of follicular cells Might be seen No or single
Colloid in background Might be seen No or trace 
Foamy macrophages Might be present No or single
Anisocytosis/anisokaryosis No or a little No
Lymphocytes/plasmatic cells No or single No
Oncocytes Non significant If > 75% of cells — there is a suspicion  
for an Hurthle neoplasm
Oncocytes have prominent nucleoli
Anisocytosis of oncocytes
Oncocytes in spatial arrangements
Indication for surgery No Yes, after confirmation of the second  
pathologist
Indication for a repeated FNAB Yes Rather no
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neoplastic lesion such as a hyperplastic 
tumour showing a high cellularity or 
lymphocytic thyroiditis (in which distur-
bances of cell structure are often present, 
see par. 13.1.1). Therefore, the statement 
“suspicious for a follicular neoplasm”, 
recommended by NCI [18] is more 
adequate than “follicular tumour” or 
“follicular neoplasm” (these statements 
may be used as clinical terms only, not as 
a cytological diagnosis) [20, 26].
 — We recommend using the term 
“Bethesda category IV” due to the 
difficulty in appropriate Polish 
translation.
 — The diagnosis “suspicious for a fol-
licular neoplasm” also involves 
a subclass “suspicious for Hurthle-
cell neoplasm”.
 — Because the authors of a new WHO 
classification accepted the evidence 
that oxyphilic adenomas and carci-
nomas are separate neoplasms and 
should not be treated any more as 
a variant of follicular neoplasms, 
the authors of current guidelines 
recommend the use of a “Hurthle 
neoplasm” category. To maintain 
consistency with Bethesda IV cat-
egory the diagnosis “suspicious 
for Hurthle-cell neoplasm” should 
be used. If a pathologist diagno-
ses follicular cells with oxyphilic 
metaplasia (oncocytic) one should 
not use the term “Hurthle cells” to 
facilitate an interpretation of cyto-
logical diag nosis and differentiation 
between lesions suspicious for a ne-
oplasm and non-neoplastic lesions: 
(ex. inflammatory lesions, showing 
oxyphilic metaplasia).
 SoR: G2; QoE: PolCon 62/62
14.5. Suspicious for malignancy (Bethesda class V).
14.5.1. Such a statement means that some fea-
tures of malignant tumours are present 
but not all that would allow a diagnosis 
of malignancy. According to the Polish 
data, the risk of cancer ranges between 
50 and 75% [21, 27].
 SoR: G1; QoE: + / PolCon 62/62
14.5.2. Suspicion for papillary thyroid carci-
noma most often concerns its follicular 
variant [17].
 SoR: G1; QoE: ++ / PolCon 62/62
14.5.3. Suspicion for MTC should be accom-
panied by serum calcitonin assessment 
(basal Ct > 100 pg/mL allows MTC to 
be diagnosed with high probability) [6].
 SoR: G1; QoE: +++ / PolCon 62/62; ATA 
GL MTC
14.5.4. Suspicion for lymphoma requires 
a second FNAB and flow cytometry [17].
 SoR: G1; QoE: ++ / PolCon 62/62
14.6. Malignant tumours (Bethesda class VI) [17].
14.6.1. This category involves the diagnosis 
of papillary thyroid cancer, anaplastic 
thyroid cancer, or metastatic carcinoma.
 SoR: G1; QoE: +++; ATA GL R12
14.6.2. MTC diagnosis and localisation of pri-
mary focus of a metastasis from other 
cancer and lymphoma require immu-
nocytochemistry [17].
 SoR: G1; QoE: PolCon 62/62
14.6.3. In the diagnosis of Bethesda class VI, 
the decision about surgery is obvious.
 SoR: G1; QoE: PolCon 61/62 ATA GL R12
15. FNAB report.
FNAB report should contain:
15.1. Information related to the nodule location and 
its features enabling its identification [9].
 SoR: G1; QoE: PolCon 62/62
15.2. Information concerning FNAB representative-
ness, both qualitative and quantitative [20].
 SoR: G1; QoE: PolCon 62/62
15.3. Description of cytological examination of each 
nodule assessed.
 SoR: G1; QoE: PolCon 62/62
15.4. Diagnostic conclusion that classifies FNAB 
findings to one of six Bethesda classes (Table 
II). See par. 16) [20].
 SoR: G1; QoE: +++ / PolCon 62/62; ATA GL R9
15.5. IMPORTANT NOTICE: It is recommended that 
a comment be attached to the FNAB report [17].
 SoR: G1; QoE: PolCon 62/62
16. Unacceptable diagnostic terminology.
16.1. The following statement should be avoided:
16.1.1. “Atypical cells have not been found”, 
“bloody smear”, “malignancy features 
have not been found”.
 SoR: G1; QoE: PolCon 62/62
16.1.2. All examples given in par. 16.1.1 should 
unequivocally evaluate whether the 
FNAB result is benign (Bethesda II) or 
non-diagnostic (Bethesda I) [20].
 SoR: G1; QoE: PolCon 62/62
16.1.3. One must not use the statement “FNAB 
result may arouse suspicion for a fol-
licular tumour”.
 SoR: G1; QoE: PolCon 62/62
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16.1.4. The statement given in par. 16.1.3 does 
not provide the clinician with sufficient 
information about whether a patholo-
gist formally diagnoses “suspicious for 
a follicular neoplasm” or whether there 
are some data suggesting this diagnosis 
but not sufficient to support it. In such 
cases the pathologist should consider 
whether or not to state a diagnosis of 
“follicular lesion of undetermined sig-
nificance”, which is clear for a clinician 
because it gives information that the 
nodule requires further diagnostics. 
Additional information “suspicion for 
a follicular neoplasm is not excluded” 
or “suspicion for a follicular neoplasm 
was considered but not all criteria are 
fulfilled” is also acceptable.
 SoR: G1; QoE: PolCon 62/62
17. FNAB reliability and limitations.
17.1. Differentiation between follicular carcinoma 
and adenoma on the basis of cytological ex-
amination is not possible [20].
 SoR: G1; QoE: PolCon 62/62
17.2. Because there is always a risk of a false nega-
tive result of FNAB clinicians should evaluate 
the presence of clinical features of malignancy 
indicating surgical treatment [21].
 SoR: G2; QoE: PolCon 62/62; ATA GL R23 and R24
17.3. This risk is usually related to insufficient 
sample cellularity, incorrect aspiration, wrong 
interpretation, or the occurrence of cystic form 
of thyroid carcinoma [18, 20].
 SoR: G2; QoE: PolCon 62/62
17.4. The risk of false positive result is 1%.
 SoR: G2; QoE: + / PolCon 62/62
18. Contraindications to FNAB [28].
18.1. Absolute.
18.1.1. Serious haemorrhagic diathesis.
18.1.2. Purulent skin lesions.
18.1.3. Lack of patient’s cooperation.
 SoR: G1; QoE: PolCon 62/62
18.2. The use of anticoagulant drugs.
18.2.1. Acenocoumarol and Warfarin.
 The authors of these recommendations 
believe, after consultation with special-
ists, that the use of acenocoumarol and 
warfarin does not constitute an absolute 
contraindication to FNAB, especially 
when a 0.4-mm diameter needle is used 
and INR ranges between 2.5–3. Replace-
ment by a low molecular weight heparin 
may be considered.
 SoR: G2; QoE: +++ / PolCon 62/62
18.2.2. Low molecular weight heparin.
 An eight-hour interval between the last 
dose of the drug and FNAB is necessary.
 SoR: G2; QoE: + / PolCon 62/62
18.2.3. Dabigatran (Pradaxa).
 A 12-hour interval between the last dose 
of the drug and FNAB is necessary.
 SoR: G2; QoE: + / PolCon 62/62
18.2.4. Rivaroxaban (Xarelto).
 A 24-hour interval between the last dose 
of the drug and FNAB is necessary.
 SoR: G2; QoE: + / PolCon 62/62
18.2.5. Clopidogrel.
 If, for cardiological reasons, drug with-
drawal is contraindicated, FNAB is ac-
ceptable in a patient using clopidogrel 
only if there is an absolute indication for 
FNAB. Replacement with a low molecu-
lar weight heparin is not justified due 
to the differences in the mechanisms of 
action of both drugs.
 SoR: G2; QoE: + / PolCon 62/62
18.2.6. Acceptable drugs:
 — Aspirin with doses < 0.3 g.
 — Non-steroidal anti-inflammatory 
drugs.
 SoR: G2; QoE: ++ / PolCon 62/62
19. FNAB complications [28].
19.1. Transient.
19.1.1. Haematoma (prevention — compression 
of FNAB site following biopsy. If deeply 
located lesions are aspirated, 30-minute 
observation is recommended).
 SoR: G2; QoE: PolCon 62/62
19.1.2. Pain and oedema (prevention — ice 
compress, paracetamol).
 SoR: G2; QoE: PolCon 62/62
19.1.3. Syncope.
 SoR: G2; QoE: PolCon 62/62
19.1.4. Infection (rare even in patients with 
immune deficiency), increased risk in 
patients infected with HIV or with diag-
nosis of diabetes mellitus, tuberculosis, 
atopic dermatitis.
19.1.4.1. Staphylococcal infection. If skin 
hygiene is poor, skin should be 
thoroughly disinfected.
 SoR: G2; QoE: PolCon 62/62
19.2. Serious — extremely rare.
19.2.1. Needle tract implantation from thyroid 
carcinoma has never been reported with 
reference to 23-gauge or smaller needle. 
These complications concerned mostly 
core biopsy.
 SoR: G2; QoE: PolCon 62/62
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19.2.2. Recurrent laryngeal nerve palsy (the 
total risk is 0.036%) — dysphonia and 
dysphasia typically develop on the 
second day after FNAB, and recovery 
takes up to four months.
 SoR: G2; QoE: PolCon 62/62
19.2.3. Haemorrhage or haematoma requiring 
surgery.
 SoR: G2; QoE: PolCon 62/62
20. Immunocytochemistry.
 Immunocytochemistry in FNAB aspirate may 
provide some information, crucial for the diagno-
sis. “Cell block” technique is a preferable method 
mainly due to the possibility to perform a few 
reactions at the same time and simultaneously 
to evaluate some features of cell architecture 
like papillary or tubular structures. The Tg and 
Ct expression should be evaluated to confirm 
thyroid origin of the neoplasm. It is characterised 
by a high specificity. However, it is difficult for 
interpretation, particularly in smears (membrane 
and cytoplasmic reaction) and due to diffusion-
related artefacts. The evaluation of TTF-1 and 
PAX 8 is characterised by a high sensitivity but 
low specificity. Therefore, if their expression has 
been demonstrated, it requires an additional 
evaluation of Tg expression. To establish the 
origin of metastatic thyroid tumour, consider-
ing the frequency of occurrence and similarity 
in cytological pictures, one should exclude:
• renal cancer (RCC+, PAX2+, CD10+) [29];
• lung adenocarcinoma (napsin A+, PAX 8+, TTF-1+, 
Tg-), squamous cell carcinoma (p63+) [30];
• head and neck squamous cell carcinoma (p63, 
CK 5,6) [31];
• breast cancer (GATTA3+) [32];
• malignant melanoma (SOX10+, HMB45) [33];
• colon adenocarcinoma (CDX2+);
• if there is a suspicion of parathyroid tumour, the 
assessment of PTH concentration in FNAB wash-
out is helpful;
• diagnosis of anaplastic thyroid carcinoma (ATC) 
may be confirmed by PAX8 expression (TTF-1 and 
Tg may be negative), p54 and a high mitotic activ-
ity of cancer cells in smear (Ki-67 > 30%).
 SoR: G1; QoE: PolCon 62/62
21. Further follow-up after non-diagnostic FNAB [5].
21.1. Cyst.
 In the case of a pure sonographic cyst without 
any solid part and failure of the first FNAB 
in obtaining diagnostic material, a repeated 
FNAB may be considered within 6–18 months. 
The risk of cancer is low, but not excluded [34]
 SoR: G2; QoE: PolCon 61/62
21.2. Solid nodule.
 A solid nodule, clinically benign with a non-
diagnostic FNAB result requires a clinical and/
or sonography follow-up and repeated FNAB, 
usually within 3–12 months, depending on 
clinical and sonography risk (see par. 3).
 SoR: G2; QoE: PolCon 61/62
21.3. Solid nodule with cystic degeneration.
 In the case of the first FNAB being non-diag-
nostic, repeated FNAB is indicated within 3–12 
months. The solid part should be biopsied [5, 9]
 ATA consider surgical treatment in the case of 
non-diagnostic FNAB. The authors of these 
recommendations propose that in such a case 
the clinical and sonography risk factors of 
malignancy (see par. 3) should be relied upon.
 SoR: G1; QoE: PolCon 61/62; ATA GL R10
22. Interval between non-diagnostic and second FNAB.
22.1. This interval should not be shorter than three 
months, unless clinical features strongly sug-
gest a very high risk of malignancy (suspicion 
of poorly differentiated or anaplastic thyroid 
carcinoma or lymphoma), or an incorrect 
FNAB procedure is highly probable.
 SoR: G2; QoE: PolCon 62/62
22.2. In the vast majority of cases, where the clini-
cal risk is not high, repeated FNAB may be 
performed 6–12 months later [19].
 SoR: G2; QoE: PolCon 62/62
23. Two non-diagnostic FNABs:
23.1. Two non-diagnostic FNABs in a cyst. If two 
FNABs in a pure cyst are non-diagnostic, it 
should be taken into consideration that cancer 
risk is very small (1%); however, it cannot be 
definitely excluded [5, 8, 9].
 SoR: G2; QoE: PolCon 62/62
23.2. Two non-diagnostic FNABs in a solid lesion [5]
23.2.1. Due to the lack of cancer exclusion and 
possible higher probability of its detec-
tion, surgery should be considered 
depending on clinical and sonography 
risk factors [8, 9].
 SoR: G2; QoE: PolCon 62/62
23.2.2. In the case of two non-diagnostic FNABs 
in a nodule subjected for further follow-
up, subsequent FNAB performed in 
another centre, should be considered.
 SoR: G2; QoE: PolCon 62/62
23.2.3. In the case of a significant lesion growth, 
surgery should be considered unless 
the clinical context explains the lack of 
adequate FNAB material [5], see also 
par. 13.
 SoR: G2; QoE: PolCon 62/62
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23.2.4. If neither nodule growth nor sonog-
raphy risk factors are present, surgical 
treatment may be considered with refer-
ence to the clinical context and a deci-
sion is made together with the patient.
 SoR: G2; QoE: PolCon
23.2.4.1. In a lesion < 1 cm in any di-
ameter, which does not show 
significant growth and clinical 
risk factors and sonography 
features of invasiveness, sur-
gery is not indicated.
 SoR: G2; QoE: PolCon 62/62
24. Further follow-up after the diagnosis of a benign 
nodule on FNAB.
24.1. Benign FNAB result does not unequivocally 
negate surgery.
 SoR: G1; QoE: + / PolCon 62/62
24.2. Follow-up of a solid nodule, with a benign 
FNAB result.
 If clinical indications and the results of other 
examinations together with patient’s prefer-
ence do not indicate surgery, further follow-up 
should consider that the risk of malignancy 
in a nodule which has undergone FNAB is 
significantly lower than that in a nodule that 
had not been biopsied [35].
 SoR: G1; QoE: ++ / PolCon 62/62
24.2.1. A solid nodule, benign on FNAB, 
requires clinical follow-up (physical 
examination or ultrasound) every 6–18 
months.
 SoR: G1; QoE: +++ / PolCon 62/62
24.2.2. Repeated FNAB is not required if no 
clinical doubt exists and the quality of the 
first FNAB is good. The frequency of the 
detection of thyroid cancer in histopathol-
ogy examination in patients with a benign 
FNAB result, subjected to surgery without 
a repeated FNAB in Poland, is 3.6% [19].
 SoR: G1; QoE: ++ / PolCon 62/62
24.2.3. Repeated FNAB in a lesion demon-
strating sonography risk features of 
malignancy with a benign FNAB result, 
makes the diagnosis more reliable and 
diminishes the risk of cancer omission.
 SoR: G1; QoE: PolCon 62/62
24.2.3.1. If no clinical risk factors exist, 
no tumour growth is observed, 
and no new sonography risk 
features have occurred, a re-
peated FNAB is usually indi-
cated no earlier than after 6–12 
months.
 SoR: G1; QoE: PolCon 62/62
24.2.3.2. If the aggravation of sonogra-
phy risk features is significant, 
particularly if signs of nodule 
invasiveness are present (par. 
3.2), FNAB may be repeated ear-
lier — no later than 3–6 months 
after [9].
 SoR: G1; QoE: ++ / PolCon 62/62
24.2.3.3. In other lesions with risk fea-
tures of malignancy, the time of 
repeated FNAB depends on the 
magnitude of clinical risk [9].
 SoR: G2; QoE: PolCon 62/62
24.2.4. Indications for a repeated FNAB within 
6–12 months may be related to nodule 
growth, the presence of clinical risk 
factors, or the lower reliability of the 
first FNAB — due to the very small le-
sion diameter or nodule location in the 
dorsal part of the thyroid lobe, leading 
to an increased risk of missing the lesion 
during FNAB.
 SoR: G2; QoE: PolCon 62/62
24.2.4.1. An increase of the nodule size is 
not a sufficient criterion of its ma-
lignancy [34], but it constitutes an 
indication for a repeated FNAB 
(if its enlargement by 20% in 
every diameter within one year 
is observed).
 SoR: G2; QoE: PolCon 62/62
24.2.4.2. The occurrence of new sonog-
raphy high-risk features of 
malignancy in a benign nodule 
on the previous FNAB indicates 
the need for a repeated FNAB.
 SoR: G1; QoE: +++ / PolCon 
62/62
24.3. The recommendations given in par. 24.1–2 also 
concern solid-cystic nodules. Repeated FNAB 
is indicated if the solid part of the nodule grows 
significantly.
 SoR: G2; QoE: PolCon 62/62
24.4. Further follow-up is acceptable, even if signifi-
cant nodule growth is observed, if the repeated 
FNAB gives a benign result [34].
 SoR: G2; QoE: PolCon 62/62
25. Further follow-up after diagnosis of a follicular le-
sion of undetermined significance.
25.1. The risk of cancer in such lesions is probably no 
higher than 5%. According to the Polish data, 
it ranges between 2.4% and 5.2%.
 SoR: G2; QoE: ++ / PolCon 62/62
25.2. Follow-up (repeated sonography every six 
months), and repeated FNAB in 6–12 months 
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(no sooner than after three months, due to 
the risk of the presence of repair changes), are 
recommended.
 SoR: G2; QoE: PolCon 62/62
25.3. If sonographic risk factors of malignancy are 
present (see par. 3.2) or the FNAB reports 
disturbances in cell architecture suggesting 
malignancy, a repeated FNAB is recommended 
after a 3–6-month interval, depending on the 
clinical risk. If a similar result is obtained, sur-
gery has to be considered, particularly if strong 
sonography risk factors or features of lesion 
invasiveness (see par. 3.2) are present or the 
FNAB report suggests malignancy.
 SoR: G2; QoE: PolCon 62/62
25.4. Surgery is recommended in nodules > 4 cm, in 
smaller lesions if a significant nodule growth 
is present or if the second FNAB indicates 
a higher cancer risk.
 SoR: G2; QoE: ++ / PolCon 62/62
25.5. If a nodule with this diagnosis has an au-
tonomous appearance in scintigraphy, further 
follow-up may be recommended, together 
with 131I treatment, because the risk of cancer 
does not exceed ≤ 2% [9].
 SoR: G2; QoE: ++ / PolCon 62/62
26. Further follow-up after the diagnosis of a lesion 
“suspicious for a follicular neoplasm”.
26.1. It has to be re-emphasised that this diagno-
sis should be stated only in cases where the 
necessity of surgical treatment is anticipated 
— to obtain material and to perform the final 
histopathological examination [20].
 SoR: G1; QoE: +++
26.1.1. The diagnosis has to be confirmed by 
another pathologist prior to surgery.
 SoR: G2; QoE: PolCon 62/62
26.1.2. If such confirmation has been achieved, 
repeated FNAB provides no further 
essential information, especially if per-
formed soon after the first biopsy.
 SoR: G1; QoE: PolCon 62/62
26.1.3. If there is no possibility to consult the 
FNAB result, surgery is acceptable in 
the case of urgent clinical indications.
 SoR: G2; QoE: PolCon 62/62
26.2. Indications for surgery if a lesion suspicious for 
a follicular neoplasm is diagnosed.
26.2.1. If the FNAB result is Bethesda IV, sur-
gery should be considered in order to 
resolve diagnostic doubts, particularly if 
clinical or sonography risk features are 
present. The risk of malignancy related 
to this Bethesda category, observed in 
a particular centre has also to be con-
sidered.
 SoR: G2; QoE: PolCon 62/62
26.2.2. Surgery constitutes the optimal way 
to establish the final diagnosis in the 
nodule classified as Bethesda class IV.
 SoR: G1; QoE: +++ 
26.2.3. In small lesions (up to 1 cm), if clinical 
and sonography risk features are absent, 
resignation from surgery and follow-up 
are acceptable only under strict sonog-
raphy and clinical monitoring.
 SoR: G2; QoE: PolCon 62/62
26.2.4. If the FNAB result is suspicious for 
Hurthle-cell neoplasm, surgery is rec-
ommended due to the risk of cancer of 
at least 15%.
 SoR: G2; QoE: PolCon 62/62
26.2.5. Intraoperative nodule examination does 
not usually contribute any important 
information.
 SoR: G1; QoE: PolCon 62/62
26.3. If the decision is to resign from surgery and 
the nodule is to be further followed, a repeated 
FNAB may be performed no earlier than after 
three months, usually after six months.
 SoR: G2; QoE: PolCon 62/62
27. Further management after the diagnosis of a suspi-
cion for a malignant neoplasm on FNAB.
27.1. Suspicion for malignancy (category V accord-
ing to the Bethesda classification) [35].
27.1.1. Surgery is recommended regardless of 
the presence of sonographic risk factors.
 SoR: G1; QoE: PolCon 62/62
27.1.2. Confirmation of FNAB diagnosis by 
a second pathologist is necessary.
 SoR: G2; QoE: PolCon 62/62
27.1.3. In the case of suspicion for malignancy, 
intraoperative histopathological exami-
nation may be considered.
 SoR: G2; QoE: ++
28. Malignant neoplasm (category VI according to the 
Bethesda classification) [27].
28.1.1. Surgery is necessary.
 SoR: G1; QoE: +++; ATA GL R12
28.1.2. Confirmation of FNAB diagnosis by 
a second pathologist is necessary.
 SoR: G2; QoE: PolCon 62/62 
28.1.3. In the case of preoperative diagnosis of 
anaplastic thyroid cancer, thyroid lym-
phoma, or metastases from other cancer, 
it is necessary to evaluate whether the 
tumour is amendable to surgery, and to 
establish further management. In the 
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case of anaplastic thyroid carcinoma, 
diagnostics should be performed with-
out delay.
 SoR: G2; QoE: PolCon 62/62
29. Indications for FNAB and its interpretation in 
children.
29.1. Childhood thyroid diseases have been cov-
ered in separate guidelines prepared by 
a group of designated specialists [36, 79].
29.2. In children surgery is undertaken more often 
because the risk of tumour malignancy is 
higher and it also concerns autonomous thy-
roid nodules [36, 37].
 SoR: G1; QoE: ++
30. Indications for FNAB and its interpretation during 
pregnancy.
30.1. Indications for FNAB in pregnant women and 
other patients are the same.
30.2. The cytological diagnosis “suspicious for a fol-
licular neoplasm” does not constitute an abso-
lute indication for surgery during pregnancy. 
Surgery, if considered, may be performed after 
delivery if sonographic appearance is stable.
 SoR: G2; QoE: + / PolCon 62/62 ATA GL R31
30.3. If low advanced papillary thyroid carcinoma 
is diagnosed during pregnancy, sonographic 
tumour monitoring should be undertaken. If 
the tumour diameter increases, surgery should 
be performed in the second trimester, before 
the 24th week of gestation. If the sonographic 
appearance is stable or cancer is diagnosed in 
the second half of pregnancy, surgery may be 
delayed until after delivery.
 SoR: G2; QoE: ++ / PolCon 62/62; ATA GL R31
31. Intraoperative histopathological examination.
31.1. Imprint cytology and frozen section (using cry-
ostat only) are included in the intraoperative 
histopathological examination. If the centre 
is equipped with instrumentation of newest 
generation, able to perform histopathological 
examination within 48 hours of surgery, no 
intraoperative examination is required.
 SoR: G2; QoE: PolCon 62/62
31.2. If follicular lesion of undetermined significance 
or lesion suspicious for a follicular neoplasm 
is diagnosed, intraoperative histopathological 
examination is not recommended.
 SoR: G2; QoE: PolCon 62/62
32. The role of core biopsy.
32.1. Core biopsy does not significantly improve the 
differentiation between cancer and follicular 
adenoma.
 SoR: G2; QoE: +
32.2. Some insufficiency in the accuracy of the FNAB 
result, as compared to core biopsy, is compen-
sated by its simplicity, lower cost, and lower 
patient discomfort related to FNAB.
 SoR: G2; QoE: +
32.3. If no other possibility to state diagnosis exists, 
core biopsy may replace FNAB.
 SoR: G2; QoE: +
33. The role of FDG-PET in the evaluation of tumour 
malignancy.
33.3.1. FDG-PET is not recommended in dif-
ferential diagnostics of thyroid nodules.
 SoR: G2; QoE: + / PolCon 62/62 ATA GL R18
33.3.2. However, if FDG-PET is performed for 
other reasons, increased focal tracer up-
take in the thyroid indicates a significant 
risk of malignancy. In such a case, one 
should follow par. 6.3 [15, 16].
34. Molecular diagnostics of thyroid nodules (gene 
expression profile and sequencing) extends initial 
diagnostics of thyroid cancer. Molecular tests help 
to distinguish between benign and malignant nod-
ules, particularly in indeterminate FNAB results 
(Bethesda III-V). Such an examination is particularly 
recommended in centres experienced in molecu-
lar investigations. One should adhere to the rule 
that the patient has to be fully informed about the 
significance of the obtained results. Cost-effective 
molecular testing, available in Polish conditions, 
should be worked out.
 SoR: G2; QoE: +/PolCon 62/62; ATA GL R13 and R14
II. Histopathological examination of 
postoperative thyroid material 
SoR: G1; QoE: PolCon 62/62; ATA GL R46
1. Recommendation related to the preparation of the 
histopathological specimen after thyroid surgery.
1.1. The management.
1.1.1. Measure and weigh the specimen.
1.1.2. Mark with ink the surface and the cut 
line before tissue fixation, if possible.
1.1.3. Orient the specimen and cut parallel 
slices 5 mm each.
1.1.4. Check whether parathyroid glands 
are present in the tissue surrounding 
thyroid gland.
1.2. General principles of grossing.
1.2.1. Type of surgery (lobectomy, isthmec-
tomy, subtotal thyroid resection, total 
thyroidectomy, etc.).
1.2.2. Weight, shape, colour, and consistency 
of the specimen.
1.2.3. Cut surface: smooth or nodular, number, 
size, colour, and appearance of nodules 
and their characteristics: cystic, solid, 
calcified, haemorrhagic, necrotic, en-
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capsulated or invasive, distance to line 
of resection.
1.2.4. Photographic documentation may be 
considered.
1.3. Sections for histology.
1.3.1. For diffuse lesions: three sections from 
each lobe and one from isthmus.
1.3.2. For a solitary encapsulated lesions up to 
5 cm in diameter: entire circumference; 
most of these sections should include 
tumour capsule and adjacent thyroid 
tissue, one additional section for each 
additional centimetre in diameter.
1.3.3. For multinodular thyroid glands: one sec-
tion of each nodule (up to five nodules) 
including rim and adjacent normal gland.
1.3.4. For papillary thyroid cancer: the whole 
thyroid gland with the assessment of 
resection lines.
1.3.5. For thyroid carcinoma other than papil-
lary: three sections of tumour, three of 
non-neoplastic gland, one from line of 
resection closest to the neoplastic lesion.
1.3.6. Take a parathyroid sample if parathy-
roid glands are present in the specimen.
1.3.7. Collect each lymph node and report 
their number.
1.3.8. Identify other anatomical structures 
present (ex. thymus) and take them 
whole for histopathological evaluation.
2. Histopathological intraoperative assessment.
2.1. The decision whether intraoperative histo-
pathological examination is necessary or not 
should be made individually in each case 
suspected for malignancy.
2.2. If there is a possibility to evaluate fresh speci-
men, the pathologist should carry out grossing 
of the specimen. In a case of the presence of 
a suspected lesion, microscopic frozen sections 
(using cryostat) should be performed.
2.3. Intraoperative histopathological examination 
allows for distinction between non-neoplastic 
goitre and papillary, medullary, and undiffer-
entiated thyroid carcinoma.
2.4. Intraoperative histopathological examination 
of lymph nodes allows for diagnosis of lymph 
node metastases and for qualification for lym-
phadenectomy.
2.5. If there is a suspicion for follicular thyroid 
carcinoma the decision referred to the extent 
of surgery should consider that final differen-
tiation between follicular thyroid adenoma 
and follicular thyroid carcinoma is possible 
only on the basis of postoperative microscopic 
study. In the case of follicular tumours, tumour 
capsule infiltration and angioinvasion have to 
be demonstrated. It is possible only in paraffin-
embedded specimens.
2.6. In the case of follicular variant of papillary 
thyroid carcinoma, imprint cytology of tumour 
cut surface is necessary because it enables the 
identification of very characteristic nuclear 
features of cancer cells (grooves and intranu-
clear inclusions).
2.7. Although most diagnoses may be unequivo-
cally stated one should remember that the 
differentiation between lymphoma and poorly 
differentiated or medullary thyroid cancer as 
well as metastatic tumours from other cancers 
(such as clear cell renal carcinoma) require im-
munohistochemistry.
3. Histopathological examination.
3.1.  Histopathological diagnosis must involve 
a precise assessment of thyroid cancer type and 
subtype, tumour diameter, and TNM staging 
(Table IV).
3.2.  In the case of lymph node metastases, their 
number and diameter should be given. The 
information whether neoplastic infiltration 
exceeds the nodule capsule and the assessment 
of the diameter of lesions in extrathyroidal and 
extranodal tissue should also be provided.
3.3.  The diagnosis should fulfil WHO histopatho-
logical criteria of thyroid tumours (Table V) 
including newly recognised cancer types with 
a significant clinical impact, such as hobnail 
variant of papillary thyroid cancer (PTC).
3.4.  The conclusion of the histopathological report 
should include TNM classification according to 
the Eighth Edition of AJCC/UICC criteria (Table 
IV and IVa).
3.5.  The following issues should be involved in the 
histopathological report.
3.5.1. Type of specimen (whether it reflects 
the extent of surgery) with the informa-
tion referred to its fixation, condition 
(any damage, intended or not), and 
topography.
3.5.2. Histopathological diagnosis with a sub-
type and the following data:
 — tumour localisation;
 — tumour size (three dimensions are 
necessary) and grossing;
 — tissue located outside the tumour;
 — tumour capsule and its condition;
 — vascular invasion (number of in-
vaded vessels: up to four or more 
than four);
 — infiltration of adjacent tissues with 
a differentiation between minimal 
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extrathyroidal extension of soft tissues 
and sternocleidomastoid muscle (T3) 
and gross extrathyroidal extension 
when cancer infiltrates subcutaneous 
fat tissue, larynx, trachea, oesopha-
gus, or recurrent laryngeal nerve (T4a);
 — radicalness of surgery including sur-
gical margins marked with ink with 
unequivocal information on whether 
they are infiltrated or not;
 — multifocality;
 — pathological lesions in thyroid, out-
side the tumour.
3.5.3. The presence and number of parathy-
roid glands and information about any 
abnormalities, if present.
3.5.4. Total number of all lymph nodes, the 
number of involved lymph nodes, and 
the diameter of a metastatic lymph 
node. Lesions < 2 mm in diameter 
should be defined as micrometastases. 
The information on whether cancer 
cells exceed the nodal capsule should 
be provided.
3.5.5. Description of extrathyroidal tissues.
3.6. In addition, a histopathological report may 
involve the following data.
3.6.1. Grading (not widely accepted in thyroid 
carcinoma).
3.6.2. Mitotic activity.
3.6.3. Presence and extent of tumour necrosis.
3.6.4. Presence of squamous metaplasia and 
clear cell changes.
3.6.5. Presence and type of tumour calcifica-
tion, stromal changes (such as diffuse 
fibrosis).
3.6.6. Results of immunohistochemistry.
3.7. Immunohistochemistry plays an important 
role in diagnostics of thyroid neoplasms.
 One should accept that in some tumour types 
they are essential.
3.7.1. In MTC immunostaining for calcitonin 
is obligatory.
3.7.2. In the case of suspicion for some PTC 
variants (such as follicular variant) it is 
worth evaluating cytokeratin 19, CD56, 
galectin 3, CITED 1, and HBME-1; how-
ever, it is not obligatory.
Table IV. 8th Edition of TNM AJCC/UICC of TNM classification of thyroid carcinoma
Primary tumor (T)
Tx Primary tumour cannot be assessed
T0 No evidence of primary tumour
T1 Tumour ≤ 2 cm in greatest dimension, limited to the thyroid
T1a Tumour ≤ 1 cm in greatest dimension, limited to the thyroid
T1b Tumour > 1 cm but ≤ 2 cm in greatest dimension, limited to the thyroid
T2 Tumour > 2 cm but ≤ 4 cm in greatest dimension, limited to the thyroid
T3 Tumour > 4 cm in greatest dimension, limited to the thyroid or tumour of any size with gross extrathyroidal extension invading only 
strap muscles (sternohyoid, sternothyroid, thyrohyoid, or omohyoid muscles)
T3a Tumour > 4 cm in greatest dimension, limited to the thyroid
T3b Tumour of any size with gross extrathyroidal extension invading only strap muscles (sternohyoid, sternothyroid, thyrohyoid, or 
omohyoid muscles)
T4 Gross extrathyroidal extension beyond the strap muscles
T4a Tumour of any size with gross extrathyroidal extension invading subcutaneous soft tissues, larynx, trachea, esophageus or recurrent 
laryngeal nerve
T4b Tumour of any size with gross extrathyroidal extension invading prevertebral fascia or carotod arthery or mediastinal vessels 
T feature is for all primary thyroid carcinoma, including anaplastic thyroid cancer
Regional lymph nodes (N)
Nx Regional nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Regional lymph node metastasis
N1a Metastases to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)
N1b Metastases to unilateral, bilateral, or contralateral cervical (levels I, II, III, IV, or V) or retropharyngeal
Distant Metastasis (M)
M0 No distant metastasis 
M1 Distant metastasis is present
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3.7.3. In the case of suspicion for poorly dif-
ferentiated thyroid carcinoma, immu-
nostaining for thyroglobulin and Ki67 
should be performed.
3.7.4. Vascular invasion in doubtful cases 
should be verified by the immunore-
activity for markers of endothelial cells 
(such as CD34 or CD 31).
3.8. In the case of suspicion for poorly differenti-
ated or undifferentiated thyroid carcinoma 
(anaplastic) the histopathological report should 
provide information about whether residual 
DTC is present in the tumour.
3.9. Due to difficulties noticed in histopathologi-
cal diagnosis of thyroid cancer it should be 
confirmed by the second pathologist from 
a centre that will carry out further treatment.
3.10. Regarding the new WHO Classification of 
Thyroid Tumours, Fourth Edition, 2017 (Table 
V), which recognises Noninvasive Follicular 
Thyroid Neoplasm with Papillary-Like Nu-
clear Features (NIFTP) as a neoplasm that 
metastasises in extremely rare cases (practically 
benign), we recommend use of this postopera-
tive diagnosis following the criteria proposed 
by WHO.
3.10.1. Postoperative, histopathological di-
agnosis of NIFTP may be stated in 
patients with preoperative diagnosis 
of Bethesda III, IV, V, and VI categories.
3.10.2. NIFTP diagnosis is not possible on the 
basis of preoperative FNAB.
3.10.3. Diagnostic criteria for NIFTP, mentioned 
before, are currently widely inves-
tigated. Thereby their update in the 
nearest future is expected. One should 
accept that NIFTP diagnosis has to be 
confirmed by another pathologist.
3.11. Doubtful cases with divergent opinions 
referred to cancer diagnosis or histological 
variant are routinely examined by pathologists 
working under Polish Group for Endocrine 
Tumours.
 SoR: G1; QoE: PolCon 62/62
Table IVa. TNM AJCC/UICC 2017 classification — staging of thyroid cancer
Stage T N M
Papillary or Follicular Carcinoma, < 55 years of age
I Any T Any N M0
II Any T Any N M1
Papillary or Follicular Carcinoma, > 55 years of age
I T1a, T1b, T2 N0 M0
II T3 N0 M0
T1, T2, T3 N1 M0
III T4a Any N M0
IVA T4b Any N M0
IVB Any T Any N M1
Medullary thyroid cancer
I T1a, T1b N0 M0
II T2, T3 N0 M0
III T1, T2, T3 N1a M0
IVA T1, T2, T3 N1b M0
T4a N1a M0
T4a Any N M0
IVB T4b Any N M0
IVC Any T Any N M1
Anaplastic thyroid cancer
IVA T1, T2, T3a N0 M0
IVB T1, T2, T3a N1 M0
T3b, T4a, T4b Any N M0
IVC Any T Any N M1
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Table V. 2017 WHO classification of thyroid tumours
Follicular adenoma 8330/0
Hyalinizing trabecular tumour 8336/1
Other encapsulated follicular-patterned thyroid tumours
Follicular tumour of uncertain malignant potential
Well-differentiated tumour of uncertain malignant potential
Non-invasive follicular thyroid neoplasm with papillary-like nucleus features
8335/1
8348/1
8349/1
Papillary thyroid carcinoma (PTC)
Papillary carcinoma
Follicular variant of PTC
Encapsulated variant of PTC
Papillary microcarcinoma
Columnar-cell variant of PTC
Oncocytic variant of PTC
8260/3
8340/3
8343/3
8341/3
8344/3
8342/3
Follicular thyroid carcinoma (FTC), NOS
FTC, minimally invasive
FTC, encapsulated angioinvasive
FTC, widely invasive
8330/3
8335/3
8339/3
8330/3
Hurthle (oncocytic) cell tumours
Hurthle cell adenoma
Hurthle cell carcinoma
8290/0
8290/3
Poorly differentiated thyroid carcinoma 8337/3
Anaplastic thyroid carcinoma 8020/3
Squamous cell carcinoma 8070/3
Medullary thyroid carcinoma 8345/3
Mixed medullary and follicular thyroid carcinoma 8346/3
Mucoepidermoid carcinoma 8430/3
Sclerosing mucoepidermoid carcinoma with eosinophilia 8430/3
Mucinous carcinoma 8480/3
Ectopic thymoma 8580/3
Spindle epithelial tumour with thymus-like differentiation 8588/3
Intrathyroid thymic carcinoma 8589/3
Paraganglioma and mesenchymal / stromal tumours
Paraganglioma
Peripheral nerve sheath tumours
— schwannoma
— malignant PNST
Benign vascular tumours
— haemangioma
— cavernous haemangioma
— lymphangioma
Angiosarcoma
Smooth muscle tumours
— leiomyoma
— leiomyosarcoma
Solitary fibrous tumour
8693/3
9560/0
9540/3
9120/0
9121/0
9170/0
9120/3
8890/0
8890/3
8815/1
→
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III. Treatment and follow-up of thyroid 
cancer
1. The authors accept ATA classification of differenti-
ated thyroid cancer (DTC; papillary or follicular) 
based on the risk of cancer relapse as a part of these 
recommendations [4] (Table VI).
 SoR: G1; QoE: +++ / PolCon 62/62 ATA GL R 48
2. Response to treatment should be classified following 
ATA 2015 recommendations (Table VII).
 SoR: G1; QoE: +++ / PolCon 62/62
3. Extent of diagnostics before surgery.
3.1. Tests, recommended before surgery, necessary 
in a case of diagnosis or suspicion of thyroid 
malignant neoplasm.
3.1.1. Medical history and clinical examina-
tion.
 SoR: G1; QoE: +++ / PolCon 61/62
3.1.2. Neck ultrasound:
 — thyroid;
 — lymph nodes.
 SoR: G1; QoE: ++ ATA GL R32
3.1.3. Ultrasound-guided FNAB — see part I 
of the Recommendations:
 — thyroid lesions;
 — suspicious lymph nodes.
 SoR: G1; QoE: +++
3.1.4. TSH evaluation to exclude thyroid func-
tional disorders.
 SoR: G1; QoE: ++
 Note! In patients, in whom suppres-
sive L-thyroxin doses are administered, 
low serum TSH level is a result of such 
treatment, and only L-thyroxine dose 
reduction before surgery is required. 
In contrast to patients with overt hy-
perthyroidism, any delay or additional 
therapy is not necessary.
 SoR: G1; QoE: +++
3.1.5. Analysis of serum total calcium con-
centration.
 SoR: G1; QoE: PolCon 61/62
3.1.6. Analysis of serum calcitonin concentra-
tion (see I, par. 2.3).
 SoR: G2; QoE: +++
Hematolymphoid tumours
Langerhans cell histiocytosis
Rosai-Dorfman disease
Follicular dendritic cell sarcoma
Primary thyroid lymphoma
9751/3
9758/3
Germ cel tumours
Benign teratoma (grade 0 or 1)
Immature teratoma (grade 2)
Malignant teratoma (grade 3)
Secondary tumours
9080/0
9080/1
9080/3
Commentary
The authors of the current classification of thyroid tumours (WHO 2017) introduced a category of encapsulated follicular-patterned thyroid tumours, 
which include three diagnoses: two of uncertain malignant potential and one benign neoplasm, which may develop distant metastases in extremely rare 
cases. The first one “well-differentiated tumour of uncertain malignant potential” is defined as a encapsulated or well demarcated tumour consisted of 
thyrocytes, which nuclei demonstrate complete or only partial features characteristic for papillary thyroid cancer and which are suspicious for tumour 
capsule infiltration or/and vascular invasion. Similar definition is related to “Follicular tumour of uncertain malignant potential”. The difference between 
both above-mentioned tumours is related to the lack of nuclear features of papillary thyroid carcinoma or their suspicion in tumour cells. Thus, this is 
an intermediate category placed between follicular adenoma and follicular carcinoma.
The introduction of above mentioned group of tumours of uncertain malignant potential is a step back in the diagnostics of thyroid neoplasms. It 
allows, without any additional examinations (immunohistochemistry) or consultations, for the diagnosis fulfilling WHO criteria, which is useless from 
the clinical point of view.
As authors of these recommendations we may only appeal to pathologists to state these diagnoses as rarely as it possible if all accessible methods 
fail to establish unequivocal diagnosis regarding tumour malignancy. 
Similarly, we also should be cautious about „non-invasive follicular thyroid neoplasm with papillary-like nucleus features” (NIFTP). This entity is 
characterized by extensive inclusion and exclusion criteria. Both good clinical experience and adequate sample quality involving the whole tumour 
capsule is required to diagnose NIFTP.
Dariusz Lange, Agata Stanek-Widera
Table V. 2017 WHO classification of thyroid tumours. cont.
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3.1.7. Chest X-ray (two views).
 SoR: G1; QoE: PolCon 61/62
3.1.8. Laryngeal examination to evaluate func-
tion of vocal cords.
 SoR: G1; QoE: PolCon 61/62
3.2. Examinations useful in differentiating diagnos-
tics and staging of cancers:
3.2.1. Neck and upper mediastinum CT scan 
if there is a suspicion of inoperable tu-
mour (ex. cT4 stage).
 Note: In DTC CT without contrast 
administration is recommended if scin-
tigraphy or 131I treatment is planned to 
be carried out within six weeks.
 SoR: G1; QoE: +++ ATA GL R33
3.2.2. CT is not a routine pre-surgery imaging 
examination indicated in all cases of 
thyroid cancer.
 SoR: G2; QoE: PolCon 62/62
3.2.3. Evaluation of the presence of distant 
metastases by other imaging examina-
tions only if indicated.
 SoR: G2; QoE: PolCon 62/62
3.2.4. In a case of MTC pre-surgical exclusion 
of the co-existence of adrenal pheochro-
mocytoma.
 SoR: G1; QoE: +++ 
3.3. Role of the evaluation of serum Ct concentra-
tion (see part I of the Recommendations) [6, 38].
3.3.1. Analysis of serum calcitonin concen-
tration is recommended in a case of 
suspicion of MTC, particularly if the 
following conditions occur:
 — a positive familial history;
 — nodular goitre in patients with pheo-
chromocytoma;
 — exhaustive diarrhoea of unknown 
origin;
 — suspicion of MTC in cytology;
 — suspicious for a follicular neoplasm 
in cytology (Bethesda IV), particu-
larly Hurthle cell neoplasm.
 SoR: G2; QoE: ++
3.3.2. Serum calcitonin level evaluation in 
a patient qualified for surgery signifi-
cantly reduces the risk of unrecognised 
MTC [38].
 SoR: G1; QoE: +++
3.3.3. The authors of these recommendations 
propose it as a compromise solution in 
view of conflicting ETA and ATA state-
ments: ETA recommendation to assess 
serum calcitonin in each case of nodular 
goitre and ATA position of no proof 
Table VI. Classification of the risk of papillary and follicular thyroid cancer recurrence according to ATA 2015 [4]
Low risk  
cancer
Papillary thyroid cancer with all of the following:
 — No local or distant metastases
 — All macroscopic tumour resected
 — No extrathyroidal extension
 — Tumour does not have aggressive histology (e.g. tall cell, hobnail variant, columnar cell carcinoma)
 — No RAI uptake outside thyroid bed in the first posttreatment whole body scan, if RAI given
 — No vascular invasion
 — Clinical N0 or ≤ 5 lymph node micrometastases (< 0.2 cm in the longest dimension)
Intrthyroidal well differentiated follicular thyroid cancer with capsular invasion, and no or minimal (< 4 foci) vascular 
invasion
Intrathyroidal papillary microcarcinoma uni or multifocal, including BRAFV600E mutated
Intermediate  
risk cancer
Microscopic extrathyroidal extension (ETE)
RAI uptake outside thyroid bed in the first posttreatment whole body scan
Aggressive histology 
Papillary thyroid cancer with vascular invasion
Clinical N1 or > 5 involved lymph nodes (0.2–3 cm)
Papillary thyroid cancer with ETE and BRAF mutated
High risk  
cancer
Gross extrathyroidal extension 
Incomplete tumor resection
Distant metastases
High postoperative serum Tg suggestive of distant metastases
Metastatic lymph nodes > 3 cm in the greatest dimension
Widely invasive follicular thyroid cancer with vascular invasion (> 4 foci)
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of the usefulness of serum calcitonin 
evaluation in a case of nodular goitre [4].
 SoR: G1; QoE: PolCon 62/62
3.3.4. Calcitonin level exceeding 100 pg/mL 
nearly unequivocally indicates MTC. 
However, it is necessary to differenti-
ate from rare neuroendocrine tumours 
secreting calcitonin, especially lung 
cancer.
 SoR: G1; QoE: ++
3.3.5. If calcitonin level ranges between 10–100 
pg/mL, the risk of a false positive result 
indicating MTC should be considered.
 SoR: G2; QoE: PolCon 62/62
4. Surgery in patients with diagnosed or suspected 
thyroid cancer.
4.1. General rules.
4.1.1. The most important part of surgical 
strategy is careful and full-profile pre-
surgical diagnostics towards cancer in 
all cases of thyroid surgery (see Part I 
of the Recommendations).
 SoR: G1; QoE: +++ ATA GL R33
4.1.2. Surgical treatment without an earlier 
FNAB may be acceptable only in excep-
tional cases.
 SoR: G1; QoE: +++ / PolCon 62/62
4.1.3. If FNAB preceding surgery was nega-
tive or did not give an unequivocal 
cancer diagnosis but the suspicion of 
cancer is still strong, intraoperative 
histopathological examination of sus-
pected tumours may be useful, but is 
not mandatory.
 SoR: G2; QoE: PolCon 62/62
4.1.4. The extent of surgery should be in line 
with the perceived cancer risk and clini-
cal staging.
 SoR: G2; QoE: PolCon 62/62; ATA GL R35
4.1.4.1 Thyroid surgery where risk of 
malignant goitre cannot be ex-
cluded, should avoid complica-
tions, especially postoperative 
hypoparathyroidism.
 SoR: G1; QoE:++ / PolCon 62/62
4.1.4.2 Thyroid surgery due to malig-
nant goitre should be carried 
out by an experienced surgeon 
in a fully equipped, specialised 
centre.
 SoR: G2; QoE: +++ / PolCon 
62/62
4.1.5. Intraoperative visualisation of the recur-
rent laryngeal nerve is recommended. 
One should also aim to protect the 
superior laryngeal nerve during intra-
operative tissue preparation next to the 
upper part of thyroid gland.
 SoR: G1; QoE: +++
4.1.6. The use of intraoperative electrostimula-
tion of the nerve (with or without neu-
romonitoring) to facilitate its identification 
and to evaluate its function is acceptable.
 SoR: G1; QoE: PolCon 62/62
Table VII. Classification of treatment response of papillary and follicular thyroid cancer according to ATA 2015 [4]
Excellent response No clinical, biochemical and structural evidence of disease:
 — Negative imaging
 — Tg (suppression) < 0.2 ng/mL
 — Tg (stimulation) < 1 ng/mL
Incomplete biochemical response Persistent abnormal Tg level in the absence of localizable disease:
 — Negative imaging
 — Tg (suppression) > 1.0 ng/mL
 — Tg (stimulation) > 10 ng/mL
 — Rising antiTg Ab
Incomplete structural response Persistent or newly identified locoregional disease or distant metastases:
 — Structural evidence of disease regardless to Tg and antiTg levels 
Indeterminate response Non-specific biochemical or structural findings that can not be unequivocally classified as 
benign or malignant:
 — Nonspecific findings on imaging studies
 — Faint RAI uptake in thyroid bed
 — Non-stimulated Tg detectable but Tg < 1.0 ng/mL
 — Stimulated Tg detectable but < 10 ng/mL
 — Tg Ab stable or declining in the absence of structural and functional disease
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4.1.7. One should aim to protect normal, 
intraoperative vascularisation of para-
thyroid glands.
 SoR: G1; QoE: +++
4.2. Surgical management if there is a suspicion for 
a follicular neoplasm on cytology (Bethesda 
class IV) [22, 24].
4.2.1. In a case of suspicion of a follicular 
neoplasm (including oxyphilic follicular 
neoplasm) there is no possibility of pre-
surgical cytological differentiation be-
tween a benign and malignant nodule.
 SoR: G1; QoE: +++
4.2.2. The principle to operate all nodules that 
are diagnosed as “suspicious for a folli-
cular neoplasm”, proposed by ATA, can-
not be literally applied in Poland due to 
its epidemiological conditioning: iodine 
deficiency in the 1980s and 1990s caused 
increased incidence of non-malignant 
thyroid nodules, which used to be di-
agnosed as follicular nodules on FNAB, 
which, according to recently proposed 
nomenclature, refers to “suspicion for 
a follicular neoplasm”. Polish published 
data estimate the risk of cancer in follicu-
lar neoplasm at 8.2–19% [25, 26].
 SoR: G2; QoE: PolCon 62/62
4.2.3. In nodules cytologically diagnosed as 
“follicular lesion of undetermined sig-
nificance” or “suspicious for a follicular 
neoplasm”, which show autonomous 
appearance in thyroid scan, the risk of 
malignancy is small, so there is no firm 
indication for surgery.
 SoR: G2; QoE: PolCon 62/62
4.2.4. In small nodules (< 2 cm in diameter) 
with cytological diagnosis “suspicious 
for a follicular neoplasm”, well con-
trolled during continuous follow-up, 
and if indicated by a repeated biopsy, it 
is accepted to resign from surgery due 
to low clinical risk.
 SoR: G2; QoE: PolCon 62/62
4.2.5. Surgery is indicated in oxyphilic nod-
ules (currently recommended diagnosis 
is: “suspicious for a Hurthle-cell neo-
plasm”), particularly if they are > 1 cm 
in diameter, because they show a higher 
risk of malignancy.
 SoR: G2; QoE: PolCon 62/62
4.2.6. At the diagnosis “suspicious for a fol-
licular neoplasm” in a single nodule 
the minimal extent of surgery involves 
hemithyroidectomy with isthmus and 
its extension to the second lobe (near 
total or total resection of the second thy-
roid lobe) depending on the individual 
risk of malignancy and presence of focal 
lesions in the second lobe.
 SoR: G2; QoE: PolCon 62/62
4.2.6.1 If the diagnosis “suspicion for 
a follicular neoplasm” concerns 
a single nodule and it is stated 
in multinodular goitre located 
only in one lobe, total or nearly 
total resection of this lobe and 
isthmus may be considered. 
Alternatively, total resection of 
that lobe, where a lesion “suspi-
cious for a follicular neoplasm” 
is located, isthmus and subtotal 
resection of contralateral lobe 
are acceptable.
 SoR: G2; QoE: PolCon 62/62
4.2.6.2 If there is a suspicion for 
a follicular or oxyphilic neo-
plasm in one of the nodules in 
multinodular goitre, bilateral 
subtotal thyroidectomy is inap-
propriate. One should follow 
par. 4.2.6.
 SoR: G1; QoE: PolCon 62/62
4.3. In a case of diagnosis of follicular lesion of 
undetermined significance (see part I) surgery 
is not obligatory; however, it may follow from 
clinical indications.
 SoR: G2; QoE: PolCon 62/62
4.3.1. As already stated above, calcitonin 
serum assessment is necessary in fol-
licular lesions (both in a “follicular le-
sion of undetermined significance” and 
“suspicious for a follicular neoplasm”, 
particularly in a diagnosis of “suspicious 
of Hurthle-cell neoplasm”), especially if 
the surgery is not performed (because 
some of them may be MTC).
 SoR: G2; QoE: PolCon 62/62
4.4. Surgical management if there is a suspicion or 
diagnosis of thyroid cancer.
4.4.1. Total/near total thyroidectomy is a basic 
surgical management.
 SoR: G2; QoE: PolCon 62/62
4.4.2. Lobectomy with isthmus is acceptable 
in patients in whom papillary thyroid 
cancer was diagnosed in a single lesion 
≤ 1 cm, cN0, if there are no indications 
for bilateral surgery and there is pa-
tient’s consent for such management.
 SoR: G2; QoE: PolCon 62/62
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4.5. Secondary thyroid surgery.
4.5.1. Secondary total thyroidectomy should be 
considered by a multidisciplinary thera-
peutic team in the case of thyroid cancer 
recognised after surgery of extent less 
than total or subtotal thyroidectomy (with 
the following exceptions given below).
 SoR: G1; QoE: PolCon 62/62; ATA GL 
R38 and R39
4.5.2. The principle of secondary total thyroid-
ectomy may be omitted if low-risk can-
cer was stated in a patient in whom total 
unilateral lobectomy with isthmus or 
total unilateral lobectomy with isthmus 
and subtotal resection of contralateral 
lobe or subtotal bilateral lobectomy were 
performed in the following situations.
 SoR: G2; QoE: PolCon 62/62
4.5.2.1. Unifocal papillary thyroid can-
cer not exceeding 1 cm in diam-
eter (pT1a) if there are no lymph 
node and distant metastases 
and careful histopathological 
analysis of postoperative tis-
sue was carried out to exclude 
multifocal tumour growth.
 SoR: G2; QoE: ++ / PolCon 62/62
4.5.2.2. Well-differentiated cancer with 
higher stage with reference to 
T feature (pT1b, pT2) if remnants 
of both lobes in ultrasound do 
not exceed 1 mL on each side 
and available data indicate 
complete surgical resection and 
low-risk cancer.
 SoR: G2; QoE: PolCon 62/62
4.5.2.3. More advanced cancer if avail-
able clinical data indicate that 
total surgery is impossible or 
does not bring any benefits for 
patients (especially in poorly 
and undifferentiated cancers).
 SoR: G2; QoE: PolCon 62/62
4.5.3. Exception from total thyroidectomy may 
refer to minimally invasive follicular 
cancer < 1 cm in diameter (pT1a), diag-
nosed after total lobectomy or subtotal 
thyroidectomy, if distant or lymph node 
metastases where not found. So far, the 
improvement of long-term outcomes 
after secondary thyroidectomy has not 
been unequivocally confirmed. The 
extent of necessary surgery should be 
defined individually by a tumour board.
 SoR: G2; QoE: PolCon 62/62
4.6. The assessment of the completeness of surgery.
4.6.1. If the extent of surgery is not unequivo-
cal, the assessment of its completeness 
is based on joint interpretation of post-
surgical histopathology, ultrasound, 
postsurgical neck radioiodine (RAI) 
scan, and thyroglobulin level. All exami-
nations should be performed no earlier 
than 1–2 months after surgery. TSH 
stimulation is necessary for neck scan 
and Tg level assessment [39].
 SoR: G2; QoE: PolCon 62/62
4.6.2. Surgery may be considered as near total 
thyroidectomy if the volume of remnant 
tissue in neck sonography does not ex-
ceed 1 mL at each side. The evaluation 
of the completeness of surgery by the 
use on ultrasound should include neck 
lymph nodes (see below, par. 5).
 SoR: G2; QoE: +++ / PolCon 62/62
4.6.3. The assessment of RAI uptake and post-
surgical thyroid scan, performed under 
TSH stimulation are useful in defining 
the extent of performed surgery; how-
ever, it is not an absolute criterion of its 
completeness. In a patient in whom total 
thyroidectomy was performed, RAI up-
take after rhTSH stimulation is usually 
less than 1%. After L-thyroxin with-
drawal (3–4-week break in L-thyroxine 
treatment) the expected RAI uptake 
is < 5%, whereas RAI uptake < 2% is 
reliable proof of total thyroid resection. 
Nevertheless, a higher RAI uptake with 
small volume of thyroid remnants on 
ultrasound is not an indication for reop-
eration. Secondary total thyroidectomy 
may be considered when ultrasound 
shows thyroid remnants significantly 
larger than 1 mL on each side (the ex-
amination should be performed after 
the recovery of a postsurgical swelling), 
if the tumour > T1 was diagnosed and 
if in intermediate and high-risk thyroid 
cancer is diagnosed. Such a decision 
should be made by a tumour board.
 SoR: G1; QoE: PolCon 62/62; ATA GL R38
5. Surgery of the lymphatic neck system in primary 
thyroid cancer.
5.1. Central neck dissection.
5.1.1. Dissection of central neck lymph nodes 
due to thyroid cancer should involve 
the group VI of neck lymph nodes — 
prelaryngeal, pretracheal, paratracheal, 
and parathyroidal lymph nodes. Such 
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dissection diminishes risk of cancer re-
lapse and significantly reduces the post-
operative Tg level. However, according 
to ATA guidelines, this dissection is not 
necessary in low-risk cancer:
 — Whenever involvement of this com-
partment or lateral neck lymph nodes 
occurs, surgery is a therapeutic proce-
dure and is definitely indicated at each 
stage of primary tumour;
 — If there are no features of nodal in-
volvement in the central neck compart-
ment, surgery is prophylactic [40, 41].
 SoR: G1; QoE: +++ ATA GL R36
5.1.2. ATA guidelines accept resignation from 
a routine prophylactic (elective) central 
neck dissection [40–42].
5.1.2.1. In low-risk papillary thyroid 
cancer, up to cT2 (particularly 
if tumour diameter is ≤ 1 cm) if 
there are no features of nodal 
involvement on preoperative 
neck ultrasound and during 
intraoperative evaluation.
 SoR: G1; QoE: ++
5.1.2.2. In well-differentiated follicular 
thyroid cancer if a diagnosis is 
known preoperatively (pres-
ence of distant metastases) and 
intraoperative assessment of 
central lymph node gives no 
suspicion of metastases.
 SoR: G2; QoE: PolCon 62/62
5.1.2.3. The relationship between 
prophylactic central neck dis-
section and the frequency of 
permanent postsurgical side-
effects suggests limitation of 
number of indications.
 SoR: G1; QoE: +++ / PolCon 62/62
5.2. Lateral lymphadenectomy in differentiated 
thyroid cancers.
5.2.1. Uni- or bilateral lateral neck lymphad-
enectomy as a modified procedure 
(without dissection of jugular vein, ster-
nocleidomastoid muscle, and XI nerve) 
is indicated if lymph node metastases 
are confirmed (by a positive FNAB or 
intraoperative biopsy) [4, 43].
 SoR: G1; QoE: ++ ATA GL R37
5.2.2. Selective resection of metastatic lymph 
nodes ("berry picking") instead of 
modified lateral lymphadenectomy in 
differentiated thyroid cancer is not an 
optimal management and should not 
be performed.
 SoR: G1; QoE: +++
5.2.3. Intraoperative bilateral biopsy of lateral 
lymph nodes is indicated for exclusion of 
lymph node metastases. If negative, stage 
N0 can be defined. If the result is posi-
tive, modified lateral lymphadenectomy 
is indicated. Such lymphadenectomy is 
a curative procedure (selective — this 
name does not refer to selective dissection 
of metastatic lymph nodes, which is not 
recommended in this situation) [43–48].
 SoR: G1; QoE: +++
5.2.3.1. Postoperative histopathologi-
cal diagnosing of metastases in 
< 5 small neck lymph nodes 
(< 2 mm in the longest dimen-
sion) is not an indication for 
secondary lymphadenectomy, 
if there are no other clinically 
apparent metastases and there 
is an option of adjuvant RAI 
therapy. 
 SoR: G1; QoE: ++ / PolCon 62/62 
5.2.3.2. The presence of central lymph 
node involvement does not 
require a lateral neck lymphad-
enectomy if there are no lateral 
lymph node metastases.
 SoR: G1; QoE: ++ / PolCon 62/62 
5.3. The extent of lymphadenectomy in MTC.
5.3.1. The extent of lymphadenectomy in he-
reditary MTC depends on the primary 
tumour diameter, serum calcitonin con-
centration, and the type of RET mutation 
— its detailed description is given else-
where in these recommendations [49].
 SoR: G1; QoE: +++
5.3.2. Central neck lymphadenectomy as 
a general rule is routine treatment in 
MTC except for patients in whom sur-
gery is carried out at a very early stage of 
the disease. Unilateral lymphadenecto-
my on the tumour side is always recom-
mended if there is enlargement of lymph 
nodes suggesting metastases or if they 
are found on FNAB. Elective surgery 
is also considered if the primary focus 
exceeds 1 cm in diameter and calcitonin 
level is high. In advanced MTC with 
a high calcitonin level bilateral neck lym-
phadenectomy should be considered.
 SoR: G1; QoE: +++
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5.3.3. In the case of prophylactic thyroidec-
tomy, performed in proto-oncogene 
RET mutation carriers, indications for 
elective lymphadenectomy depend on 
type of germinal RET mutation (i.e. type 
of hereditary cancer) and age when the 
surgery is performed as well as on the 
current calcitonin level [49].
 SoR: G1; QoE; ++
5.4. Extent of lymphadenectomy in poorly and 
undifferentiated (anaplastic) thyroid cancer.
5.4.1. In poorly and undifferentiated (anaplas-
tic) thyroid cancers elective (routine) 
lymphadenectomy is recommended. 
However, usually the advancement of dis-
ease unequivocally suggests lymph node 
involvement, and the extent of surgery 
depends on whether these tumours are 
resectable or not. In undifferentiated (ana-
plastic) thyroid cancer a lateral neck dis-
section Jawdynski-Crile may be necessary.
 SoR: G1; QoE: +++
5.5. Surgery of mediastinal lymph nodes.
5.5.1. Mediastinal lymph nodes are operated 
in the case of confirmed metastases or 
if suspected lymph nodes are present. 
There is no indication for elective me-
diastinal lymph node dissection as well 
as for a preoperative CT scan.
 SoR: G1; QoE: ++
6. Multiple organ surgery.
6.1. In differentiated thyroid cancers multiple 
organ surgery may be carried out if there 
is infiltration of adjacent structures (larynx, 
oesophagus, blood vessels) and if complete 
resection (so called R0 resection) is possible. 
In undifferentiated cancer confirmed in his-
topathology the infiltration of adjacent organs 
requires a combined therapy.
 SoR: G1; QoE: ++
7. Complications after surgery of thyroid carcinoma.
7.1. The most common complications after surgery 
are recurrent laryngeal nerve palsy and hy-
poparathyroidism.
 SoR: G1; QoE: +++
7.1.1. Both complications may be transient or 
permanent. The frequency of perma-
nent side effects is an important meas-
ure of a particular centre’s experience; 
however, it is also related to the stage 
of the disease.
 SoR: G1; QoE: ++
7.1.2. Centre experience in central and lateral 
lymphadenectomy is much more impor-
tant than experience in total thyroidec-
tomy to decrease the general frequency 
of complications.
 SoR: G1; QoE: ++
7.2. Laryngeal recurrent nerve palsy.
7.2.1. Laryngological examination to evalu-
ate vocal cords and indications for the 
treatment of this complication should be 
performed before and after each surgery.
 SoR: G1; QoE: PolCon 62/62
7.2.2. In the case of vocal cord paresis, pho-
niatric voice rehabilitation is neces-
sary, whereas if this complication is 
permanent, remedial surgery may be 
considered.
 SoR: G1; QoE: ++
7.2.3. Bilateral vocal cord paresis in general 
requires tracheostomy immediately af-
ter surgery.
 SoR: G1; QoE: +
7.3. Hypoparathyroidism.
7.3.1. The rules referring to the treatment of 
hypoparathyroidism follow the recom-
mendations of the European Society of 
Endocrinology (ESE) [50].
7.3.2. Strict monitoring of serum-ionised (or 
corrected) calcium level is necessary 
immediately after surgery for the evalu-
ation of parathyroid function.
 SoR: G1; QoE: +++
7.3.3. PTH assessment immediately after sur-
gery may support the evaluation of the 
risk of hypoparathyroidism.
 SoR: G1; QoE: ++
7.3.4. If hypoparathyroidism lasts longer than 
a few days after the operation, it should 
be evaluated by more detailed tests — it 
is advisable to assess not only calcium but 
also serum PTH and phosphate levels.
 SoR: G1; QoE: +++
7.3.5. Transient hypoparathyroidism recovers 
usually in 1–6 months; however, it may 
disappear even later, after 1–2 years. 
Therefore, assessment of indications 
for treatment continuation should be 
repeated six months, a year, and two 
years after operation [51]. 
 SoR: G1; QoE: ++
7.3.6. To avoid clinical symptoms of hypocal-
caemia, serum-ionised calcium (or cor-
rected) should be maintained at lower 
range of the normal result or slightly 
below it. Calciuria should be maintained 
within the normal range, respectively to 
sex. Serum phosphate and magnesium 
concentration should be maintained 
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within normal range, whereas calcium-
phosphate index should remain below 
4.4 mmol2/L2 (55 mg2/dL2).
 SoR: G1; QoE: ++
7.3.7. The treatment of hypoparathyroidism 
involves calcium supplementation and 
active vitamin D analogues.
 SoR: G1; QoE: +++
7.3.8. Biochemical monitoring of hypopar-
athyroidism should involve analysis of 
serum-ionised (or corrected) calcium, 
phosphate, magnesium, creatinine 
every 3–6 months. In the case of treat-
ment modification biochemical analyses 
should be carried out up to two weeks. 
Calciuria may be evaluated less fre-
quently (every year or two).
 SoR: G1; QoE: PolCon 62/62
7.3.9. In the case of hyperphosphatemia and/
or elevated calcium-phosphate index, 
a low phosphate diet and/or correction 
of calcium and vitamin D substitution 
may be considered. Hypercalciuria may 
require a low-sodium diet, decrease of 
calcium substitution, and/or administra-
tion of thiazide diuretics.
 SoR: G1; QoE: PolCon 62/62
7.3.10. Because active analogues of vitamin 
D do not provide adequate 25-OH-D3 
concentration at tissue level serum 25-
OH-D3 concentration above 30 ng/mL 
should be obtained using vitamin D 
supplementation.
 SoR: G1; QoE: ++
7.3.11. PTH evaluation allows distinguishing 
between hypoparathyroidism and 
other reasons of hypocalcaemia. Normal 
PTH level is an indication to gradually 
decrease substitution doses.
 SoR: G1; QoE: +++
8. Evaluation of cancer staging should be updated at 
subsequent diagnostics and therapy follow-ups [52].
8.1. According to TNM classification (the year of 
the last update should be provided). Currently 
the Eighth Edition of AJCC/UICC classification 
from 2017 is obligatory (Table IV).
 SoR: G1; QoE: PolCon 62/62
8.2. According to ATA 2015 classification (Table VI) 
[52].
 SoR: G1; QoE: +++ ATA GL R49
9. RAI treatment.
9.1. General rules obligatory in RAI treatment: the 
patient should be fully informed about the 
treatment goal, its course, including radiation 
safety procedures, possible consequences, and 
contraindications. Written, informed consent 
is required [53].
 SoR: G1; QoE: PolCon 62/62
9.1.1. The aim of RAI treatment:
 — To destroy thyroid remnants after 
surgery (ablation of thyroid rem-
nants);
 — Sterilisation of the remaining cancer 
microfoci localised in the thyroid 
bed and lymph nodes (adjuvant 
therapy);
 — Sterilisation of distant micrometas-
tases.
 SoR: G1; QoE: +++; ATA GL R51
9.2. Indications for RAI treatment.
9.2.1. Indications for RAI treatment may be 
considered only in DTC patients.
 SoR: G1; QoE: +++
9.2.2. There is no indication for RAI treatment 
in patients with ATC and MTC.
 SoR: G1; QoE: +++
9.3. Adjuvant RAI therapy [54].
9.3.1. Adjuvant RAI therapy concerns the 
patients showing no signs of persistent 
disease after radical surgery; however, 
possible cancer microdissemination is 
assumed. As a principle, patients with 
apparent distant metastases are not 
subjected to RAI adjuvant therapy.
 SoR: G1; QoE: +++ / PolCon 62/62
9.3.2. Both oncological treatment and ablation 
of thyroid remnants are considered as 
adjuvant therapy. These managements 
have different aims.
9.3.2.1. Ablation of thyroid remnants 
after surgery may be consid-
ered in low-risk patients. This 
treatment is to facilitate further 
disease monitoring using thy-
roglobulin measurements [55].
 SoR: G1; QoE: PolCon 62/62; 
ATA GL R51
9.3.2.2. The goal of adjuvant therapy 
is to sterilise possible cancer 
microfoci that are not detected 
by other examinations [39].
 SoR: G1; QoE: +++
9.3.3. Postoperative RAI treatment should be 
considered in all patients with papillary 
and follicular thyroid cancer staged 
pT3-T4N0 and in all patients staged N1, 
regardless of tumour diameter after 
previous total thyroidectomy.
 SoR: G1; QoE: +++
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9.3.4. Benefits of RAI administration in pa-
tients staged T1b-T2N0M0, have not been 
unequivocally proven.
 SoR: G2; QoE: ++ ATA GL R51
9.3.4.1. However, RAI treatment is rec-
ommended in this subgroup of 
patients if postoperative diagnos-
tics shows serum thyroglobulin 
level > 10 ng/mL or RAI uptake 
outside thyroid bed [39].
 SoR: G2; QoE: +++
9.3.4.2. Good previous experience of 
Polish centres speaks in fa-
vour of routine indications for 
this treatment also in patients 
staged T1b-T2N0M0 without in-
creased risk of cancer recur-
rence. The decision regard-
ing RAI treatment should be 
individualised and discussed 
with a patient, considering its 
potential benefits and risk.
 SoR: G1; QoE: PolCon 62/62
9.3.5. In low-risk patients, staged pT1aN0M0, 
who demonstrate a very low risk of 
cancer relapse, RAI treatment is not 
necessary [54, 56].
 SoR: G1; QoE: +++; ATA GL R51
9.3.6. RAI treatment may complement the 
operation of incomplete thyroidectomy 
if there are contraindications for second-
ary total thyroidectomy or if a patient 
refuses surgery.
 SoR: G1; QoE: PolCon 62/62
9.4. Indications for thyroid ablation in a patient 
with distant metastases.
 If distant metastases showing no RAI uptake in 
diagnostic whole-body scan are present and si-
multaneously significant RAI uptake in thyroid 
bed is noticed, it is necessary to destroy thyroid 
remnants by ablative RAI dose administration 
before the final evaluation of metastases RAI 
avidity.
 SoR: G2; QoE: ++ / PolCon 62/62
9.5. RAI activity used for adjuvant treatment.
9.5.1. RAI activities applied for ablation range 
between 1.1 and 3.7 GBq (30–100 mCi). 
So far, there are no convincing data 
speaking in favour of one, defined dose. 
The most positive Polish experiences 
refer to RAI activities of 2.2–3.7 GBq 
(60–100 mCi) [57].
 — Lower RAI activities may be used 
in low-risk patients complying with 
the rule that a single administered 
activity should be no less than 1.1 
GBq (30 mCi);
 — The preparation for RAI ablation 
with the use of thyrotropin alpha is 
optimal with regard to the quality 
of life;
 — If the risk of cancer microdissemina-
tion is high, administration of higher 
RAI activities of 3.7–5.5 GBq (100–150 
mCi) may be justified, especially in 
high-risk cancer patients.
  SoR: G1; QoE: +++
9.6. Indication for RAI treatment in disseminated 
thyroid cancers [58].
9.6.1. Treatment of disseminated DTC may 
be carried out with radical or palliative 
intent.
 SoR: G1; QoE: +++
9.6.2. Radical treatment is possible in these 
DTC patients with RAI-avid metastases 
showing RAI uptake strong enough to 
respond to sterilising effect of ionis-
ing radiation — microdissemination 
or dissemination in which none of the 
metastases exceed 1 cm in diameter and 
all of them show iodine uptake.
 SoR: G1; QoE: +++
9.6.3. Palliative treatment may be considered 
in DTC patients with inoperable pri-
mary tumour, inoperable local recur-
rence, or presence of distant metastases 
with iodine uptake insufficient to allow 
a sterilising effect of ionising energy. Ra-
dioiodine may then reduce the tumour 
size and slow cancer progression as well 
as alleviate disease symptoms (ex. pain).
 SoR: G1; QoE: +++
9.7. Qualification for RAI therapy.
 The patient should be informed about the 
aim of treatment, its course, including the 
principles of radiological protection, possible 
consequences, and contraindications.
 SoR: G1; QoE: PolCon 62/62
9.7.1. Before RAI treatment of thyroid cancer, 
the following qualifying examinations 
should be performed and its goal should 
be defined.
 In each case the following procedures 
are necessary:
 — patient’s history and clinical exami-
nation;
 — neck ultrasonography;
 — assessment of Tg and anti-Tg au-
toantibodies;
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 — haematology and serum calcium 
(ionised or total) concentration.
 SoR: G1; QoE: +++ / PolCon 62/62
9.7.2. Imaging necessary if distant metastases 
are suspected [59]:
 — CT or MRI of selected areas. One 
should remember that the interval 
between iodide contrast administra-
tion and RAI treatment should not be 
shorter that one month;
 — whole-body scan to localise bone 
metastases (usually 99mTc MDP or 
Na18F PET);
 — FDG FDG-PET-CT scan in selected 
cases [60].
 SoR: G1; QoE: +++
9.7.3. Analysis of iodine urinary excretion 
allows exclusion of stable iodine con-
tamination [61]:
 — There are no data demonstrating 
whether, considering the present 
iodine supply in Poland, any low-
iodine diet is necessary before RAI 
treatment [61]. However, it should 
be emphasised that the efficacy of 
RAI treatment in Poland is compa-
rable with European results, despite 
no recommendation for such a diet. 
As the supply of iodine in food in-
creases, such an indication may arise;
 — Low-iodine diet may be ordered 1–2 
weeks before radioiodine treatment 
(see www.thyca.org).
 SoR: G2; QoE: PolCon 62/62
9.8. Contraindications to RAI treatment.
9.8.1. Absolute contraindications involve 
pregnancy (in fertile female patients, 
pregnancy should be excluded by 
a pregnancy test) and breastfeeding 
(time interval between completed breast-
feeding and RAI treatment should be at 
least six weeks). Patients should not con-
tinue nursing after RAI treatment [62]. 
 SoR: G1; QoE: +++
9.9. Course of RAI treatment.
9.9.1. RAI treatment is conducted in licenced 
centres.
 SoR: G1; QoE: PolCon 62/62
9.9.2. RAI treatment of thyroid cancer is pos-
sible only if sufficient stimulation of can-
cer cells with endogenous or exogenous 
thyrotropin (rhTSH) can be achieved:
 — Recombinant TSH — thyrotropin 
alpha allows adjuvant therapy to 
be carried out without L-thyroxine 
withdrawal, which prevents side-
effects related to hypothyroidism 
and decreases exposure of healthy 
tissues to ionising radiation;
 — RAI treatment with thyrotropin 
alpha;
 L-thyroxine is not withdrawn. One 
package of rhTSH includes two ampules 
of thyrotropin alpha, 0.9 mg each. On 
the first day of treatment, after routine 
tests, the patient receives an intramus-
cular injection of 0.9 mg of thyrotropin 
alpha dissolved in 1 mL of attached dis-
solvent; the dose is repeated after 24 h.
 RAI treatment is applied after the next 
24 hours. Whole-body scan is performed 
no sooner than three days after RAI 
administration. Tg concentration test is 
performed 2–6 days after the onset of 
thyrotropin alpha administration. Some 
centres take blood sample on the second 
day, the others prefer day 6; however, 
they are aware of a possible false in-
creased result after RAI treatment. This 
decision should be made according to 
the particular centre’s experience;
 — Treatment after interval in thyroxine 
treatment;
 RAI ablation after an interval in L-thy-
roxin administration is a second option 
in adults if stimulation with thyrotropin 
alpha is impossible. RAI treatment is 
introduced after 4–6 weeks of thyroxine 
withdrawal (during the first 2–4 weeks 
triiodothyronine is administered in the 
doses to maintain euthyreosis, and dur-
ing last two weeks no thyroid hormone 
is administered). Serum TSH level 20–30 
IU/L is the necessary condition for RAI 
treatment.
 SoR: G1; QoE: ++ ATA GL R54
9.10. When RAI treatment should be administered.
9.10.1. The optimum time is four weeks after 
completed surgery, when the wound is 
healed and swelling reduced, Tg level 
is lowered, and there are no immediate 
or transient postsurgical complications.
 SoR: G1; QoE: PolCon 62/62
9.10.2. RAI therapy up to three months after 
surgery is recommended; however, if 
this time is longer than 9–12 months the 
treatment is delayed [55].
 SoR: G1; QoE: PolCon 62/62
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9.10.3.  If the patient still shows cancer remis-
sion one year after surgery, despite no 
RAI administration after surgery, indi-
cations for adjuvant therapy become 
doubtful.
 SoR: G1; QoE: PolCon 62/62
9.11. Post-therapeutic whole-body scan.
 The treatment should be finalised with 
a whole-body scan (a post-therapeutic scan) to 
assess RAI uptake in the patient’s body.
 SoR: G1; QoE: +++
9.12. Information which should be provided after 
completed RAI treatment.
9.12.1. After RAI treatment, the patient should 
be informed of the results of performed 
tests (neck ultrasonography, TSH level, 
stimulated serum Tg level, post-thera-
peutic scan, and others) with respect to 
the following issues:
 — whether the results suggest persis-
tent disease;
 — how to interpret neck uptake, if 
present;
 — the patient’s risk category if there 
is no evidence of persistent disease;
 — where and when follow-up examina-
tions are to be performed.
 SoR: G1; QoE: PolCon 62/62
9.12.2. After RAI therapy the patient should 
receive full information regarding 
whether and for how long to avoid 
contact with other people, especially 
with children and pregnant women. 
On average, 1–2 weeks after adjuvant 
RAI treatment following radical surgery 
is enough.
 SoR: G1; QoE: PolCon 62/62
9.13. RAI treatment of DTC dissemination or local 
recurrence.
9.13.1. RAI therapy in disseminated cancer is 
usually carried out after L-thyroxine 
withdrawal.
 SoR: G1; QoE: +++; ATA GL R53
9.13.2. Therapy of metastases with thyrotro-
pin alpha may be conducted under 
clinical trials held in centres where full 
monitoring and treatment of possible 
side-effects as well as the assessment of 
its outcomes are available.
 SoR: G1; QoE: ++ / PolCon 62/62
9.14. Dosimetry of RAI treatment.
9.14.1. Currently, there are no defined principles 
of dosimetry planning referred to RAI 
treatment. There are no widely accepted 
methods of therapeutic dose individuali-
sation, that would safely sterilise cancer 
lesions without excessive side effects to 
healthy organs. Therefore, pre-therapeu-
tic dosimetry is not obligatory.
 SoR: G2; QoE: +
9.15. Complications after RAI treatment and how 
to avoid them.
9.15.1. After exceeding a cumulative dose of 
18.5 GBq (500 mCi) a cost-benefit analy-
sis should be performed, concerning the 
enhanced radiogenic risk of occurrence 
of secondary cancer.
 SoR: G1; QoE: PolCon 62/62
9.15.2. Contraception is recommended for 6–12 
months in women and 4–6 months in 
men after RAI therapy.
 SoR: G1; QoE: PolCon; 62/62 
10. Teleradiotherapy.
 Teleradiotherapy of neck and mediastinum is recom-
mended [63]:
 — in undifferentiated/ anaplastic thy-
roid cancer;
 — after non-radical surgery of DTC, if 
secondary surgery or radioiodine 
treatment is not possible;
 — may be considered after non-radical 
surgery in MTC.
SoR: G2; QoE: PolCon; 62/62 
10.1. Adjuvant teleradiotherapy.
10.1.1. In radically operated DTC usually 
there are no indications to adjuvant 
teleradiotherapy. It may be considered 
in advanced locoregional cases after R1/
R2 surgery [63, 64].
 SoR: G1; QoE: +++
10.1.2. There is no evidence of effectiveness of 
adjuvant teleradiotherapy in MTC after 
radical surgery.
 SoR: G1; QoE: PolCon 62/62
10.1.3. It may be considered in patients with 
MTC lymph node metastases, in whom 
calcitonin level does not normalise after 
surgery and there are no data suggest-
ing distant metastases.
 SoR: G2; QoE: + / PolCon 62/62
10.2. Teleradiotherapy procedures.
10.2.1. Radical teleradiotherapy involves the 
administration of 50–60 Gy on the re-
gion neck lymphatic system and 60–66 
Gy on thyroid bed/tumour [63, 65, 66].
 SoR: G1; QoE: +++
10.2.2. Conformal radiotherapy with modu-
lated dose intensity is recommended if it 
is possible in a particular centre [67–71].
 SoR: G1; QoE: +++
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10.2.3. Palliative teleradiotherapy is used in 
inoperable thyroid cancer [72–74].
 SoR: G1; QoE: +++
10.2.4. Palliative teleradiotherapy of metasta-
ses, including radiotherapy to control 
pain, is used in thyroid cancer according 
to the principles applied in other types 
of cancer [72, 74, 75].
 SoR: G1; QoE: +++
11. Assessment of the efficacy of combined treatment.
11.1. In patients who do not demonstrate an increase 
of Tg serum concentration during L-thyroxine 
treatment the assessment should be carried 
out 12 months after adjuvant RAI treatment.
 SoR: G1; QoE: +++
11.2. DTC remission may be diagnosed if patients 
after total thyroidectomy and adjuvant RAI 
therapy do not demonstrate any symptoms of 
persistent disease in imaging examinations or 
an increase in serum Tg level after TSH stimu-
lation. Such tests are particularly reliable in the 
absence of anti-Tg autoantibodies.
 SoR: G1; QoE: +++ 
11.3. Minimal RAI uptake in thyroid bed is not 
unequivocal with ineffective ablation, and it 
does not constitute an indication for another 
RAI treatment itself, if: a) other tests do not 
show recurrent disease, b) stimulated Tg does 
not exceed 1–2 ng/mL, and c) thyroid remnants 
are absent in ultrasound.
 SoR: G2; QoE: ++
12.  Follow-up of the patients in whom excellent treat-
ment response is diagnosed.
 The criterion of persistent remission, stated after 
primary treatment, is a combination of negative neck 
ultrasound and TSH-stimulated serum Tg level ≤ 1 
ng/mL and simultaneously the lack of other features 
of persistent or recurrent disease [52].
 SoR: G1; QoE: +++
12.1. The frequency of the above-mentioned ex-
aminations is given below. However, it seems 
that at least one examination confirming this 
condition should be performed 3–5 years after 
the first diagnosis of DTC remission.
 SoR: G1; QoE: +++ / PolCon 62/62
12.2. Whole-body scan is currently not routinely 
performed in the follow-up of further course 
of the disease in patients showing excellent 
treatment response.
 SoR: G1; QoE: +++
12.2.1. However, the authors of these recom-
mendations believe that there is no 
reason to resign from whole-body scan 
together with an examination evaluat-
ing treatment efficacy with Tg stimula-
tion test, because in the case of serum Tg 
increase simultaneously the information 
about the presence of any RAI-avid 
cancer foci is provided.
 SoR: G1; QoE: PolCon 62/62
12.2.2. In a patient in whom the first evalua-
tion after treatment revealed excellent 
response and a further course of disease 
is asymptomatic, control Tg tests do not 
require TSH stimulation.
 SoR: G1; QoE: +++
13. Interpretation of serum Tg results in DTC patients.
13.1. Because increasing serum Tg constitutes the 
defined criterion for the detection of DTC re-
currence, it is important to evaluate this marker 
in the same centre by the same method.
 SoR: G1; QoE: +++
13.1.1. Optimally, for Tg estimation methods 
standardised to Certified Reference Ma-
terial 457 (CRM-4570) should be used. 
Each laboratory should characterise 
the functional sensitivity of its own Tg 
analysis method [76].
13.2. Tg assessment should be accompanied by the 
evaluation of Tg antibodies, which should be 
performed at least once a year.
 SoR: G1; QoE: +++
13.2.1. If anti-Tg antibodies are present, low 
serum Tg level cannot be a fully reliable 
criterion of treatment response.
 SoR: G1; QoE: +++
13.3. Interpretation of serum Tg level should refer 
to earlier Tg results, level of Tg antibodies, 
present and previous TSH level, as well as 
extent of previous surgery and RAI treatment.
 SoR: G1; QoE: +++
13.4. Ultrasensitive methods of serum Tg evalua-
tion (functional sensitivity of 0.1 ng/mL) are 
recommended.
 SoR: G1; QoE: +++
13.5. During the first five years after primary treat-
ment in patients with excellent treatment 
response, if there are no other risk factors, it 
is recommended that Tg evaluation is main-
tained every 6–12 months, and later these 
intervals may be longer. 
 SoR: G1; QoE: PolCon 62/62
13.6. If the patient did not undergo total thyroid-
ectomy and/or RAI therapy, the serum Tg 
level may be higher than 1 ng/mL, and only 
increasing Tg levels may speak for suspicion 
of cancer progression. Time intervals between 
subsequent Tg evaluations should at least fol-
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low the rules given in par. 13.5. If it is indicated, 
time intervals should be shorter.
 SoR: G1; QoE: ++
13.7. Tg level should not constitute the only factor 
monitoring cancer remission in DTC patients. 
As well as the patient’s history and physical 
examination, at least neck ultrasound should 
be performed in a similar time period [77].
 SoR: G1; QoE: ++
14.  Principles of the follow-up of DTC patients whom 
anti-Tg antibodies are present.
14.1. Neck ultrasound is the main follow-up ex-
amination in patients after radical surgery, in 
whom the presence of anti-Tg antibodies make 
reliable Tg level measurements and interpreta-
tion impossible. One should remember that 
medical history and physical examinations 
are necessary to determine the indications for 
other imaging studies.
 SoR: G1; QoE: +++
15. Neck ultrasound in the evaluation of treatment ef-
ficacy and follow-up in DTC.
 Neck ultrasound should be carried out every 6–12 
months during first five years and then less fre-
quently. In a case of suspicion of recurrence, the 
time intervals should be shorter. The diagnosis of 
cancer lesions in thyroid bed or enlarged lymph 
nodes are indications for FNAB, especially if the 
appearance of neck lymph nodes suggests their 
metastatic character (transversal diameter > 5 mm, 
loss of hilar architecture, heterogenic echotexture 
with cystic areas, round shape, peripheral or mixed 
vascularity, calcifications). See part I, par. 11.2.
 SoR: G1; QoE: +++
15.1. If a suspected lymph node is < 1 cm in diam-
eter, its follow-up may be accepted and FNAB 
may be performed in the case of its further 
growth.
 SoR: G2; QoE: PolCon 62/62
15.2. Tg assessment in the aspirate taken on FNAB 
may be helpful in a diagnosis of lymph node 
metastasis.
 SoR: G2; QoE: +++
15.3. Normal serum Tg level does not exclude lymph 
node metastases.
 SoR: G1; QoE: +++
16. Whole-body scan after RAI administration.
16.1. Isotope examinations (particularly neck and 
whole-body scans) are usually useful for the 
first evaluation of RAI treatment efficacy; 
however, they are not obligatory.
 SoR: G1; QoE: PolCon 62/62
16.1.1. However, if such examinations per-
formed after RAI treatment indicate 
a very low risk of cancer relapse in 
a low-risk patient after radical surgical 
approach, it is acceptable to resign from 
diagnostic RAI scans.
 SoR: G1; QoE: +++
16.1.2. In the case of an increase in serum Tg 
level (evaluated on L-thyroxine therapy 
or after TSH stimulation) neck and 
whole-body scans are obligatory to lo-
calise RAI-avid cancer foci and to assess 
indications for RAI treatment.
 SoR: G1; QoE: +++
16.1.3. Routine, periodic whole-body scan in 
the further follow-up of patients, in 
whom cancer remission is stated, is not 
necessary because the chance of diag-
nosing RAI-avid recurrence without 
earlier increase in serum Tg level is low.
 SoR: G1; QoE: +++
17.  CT and MRI.
17.1. CT and/or MRI are performed if there is a sus-
picion of cancer recurrence resulting from an 
increasing serum Tg level or other symptoms. 
However, one should remember that CT with 
contrast administration attenuates RAI avid-
ness for at least two months or longer.
 SoR: G1; QoE: ++
17.2. Chest CT scan is performed as the first imaging 
in the case of serum Tg increase.
 SoR: G1; QoE: +++
17.3. Suspicion of bone metastases, stated on the 
basis of patient’s history, physical examina-
tion, or other examination, is an indication for 
bone scan.
 SoR: G1; QoE: +++
17.4. FDG-PET/CT in useful to localise cancer 
relapse or distant metastases, especially in 
patients in whom serum Tg increase is not 
accompanied by the detection of cancer foci 
by other classical imaging examination and 
RAI whole body scan. It should be added that 
the intensity of glucose metabolism in cancer 
foci demonstrates a prognostic significance 
and that in some patients an increased glu-
cose metabolism is revealed only after TSH 
stimulation [78].
 SoR: G1; QoE: +++
17.5. A negative FDG PET/CT does not exclude DTC 
dissemination [60].
 SoR: G1; QoE: +++
18. Treatment with L-thyroxine in DTC patients.
18.1. Hormonal therapy with L-thyroxine is an 
essential part of a combined DTC treatment.
 SoR: G1; QoE: +++
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18.2. The goal of L-thyroxine therapy in DTC pa-
tients is:
 — supplementation of hormonal deficiency 
(substitutive treatment);
 — reduction of the risk of cancer relapse 
because TSH is a growth factor for cancer 
cells (suppressive treatment is currently 
considered only in high-risk patients or in 
patients who do not demonstrate excellent 
treatment response).
 SoR: G1; QoE: +++
19. Indications for TSH suppression.
19.1. Full TSH suppression (TSH < 0.1 mU/L) is 
necessary for the following reasons:
 — in patients with persistent, clinically appar-
ent DTC symptoms;
 — in patients with incomplete biochemical 
response according to ATA guidelines, in 
whom clinically apparent disease is not 
present, but stimulated serum Tg level (> 
10 ng/mL) and/or serum Tg level on thy-
roxine suppressive doses (> 1 ng/mL) are 
elevated or anti-Tg level increases.
 SoR: G1; QoE: ++
19.2. Full TSH suppression may be considered in 
patients demonstrating a high risk of relapse if 
there are no contraindications for suppressive 
treatment or treatment benefits compensate 
the risk related to suppressive treatment.
 SoR: G1; QoE +++
19.3. Proof confirming safety of the resignation from 
L-thyroxine suppressive therapy has been pub-
lished with reference to the lowest-risk group:
 — patients staged pT1aN0M0;
 — patients staged pT1b-T2N0, radically treated, 
in whom excellent treatment response has 
been achieved.
 In these patients, substitutive L-thyroxine doses 
should be administered. Incomplete TSH sup-
pression (TSH 0.1–0.4 mU/L) is also acceptable, 
but the decision should be personalised.
 SoR: G1; QoE: +++
19.4. In these patients, in whom an excellent treat-
ment response has been confirmed by all pos-
sible methods, among them by a low serum Tg 
level with the absence of anti-Tg antibodies, 
and the remission lasts at least five years, sub-
stitutive L-thyroxine treatment is acceptable.
 SoR: G1; QoE: +++
19.5. In all patients who undergo DTC treatment an 
increase of serum TSH level > 2 mU/L should 
be avoided except for short periods of TSH 
stimulation due to follow-up examinations.
 SoR: G1; QoE: +++
19.6. In patients on full TSH suppression the addi-
tion of a beta-blocker or ACE inhibitor to pre-
vent cardiac hypertrophy may be considered.
 SoR: G1; QoE: ++
20. Dosage of L-thyroxine.
20.1. L-thyroxine dose is established individually, 
and is administered once a day, fasting, 20–30 
minutes before food intake. Regardless of the 
fact that all L-thyroxine forms registered in Po-
land are considered equal, there are some dif-
ferences in their bioavailability, and therefore 
one drug should not be replaced by another 
without justification and the decision of an 
aware physician because it may influence the 
precise serum TSH control.
 SoR: G1; QoE: +++
20.2. If L-thyroxine dose requires modification, small 
dose changes are acceptable (in general, not 
higher than by 25 µg daily) and subsequent 
assessment of TSH level should be done in 
6–8 weeks.
 SoR: G1; QoE: +++
20.3. Serum TSH level should be measured every 
3–6 months, using a third-generation assay, in 
the morning before L-thyroxine dose intake.
 SoR: G1; QoE: +++
20.4. Treatment-related side effects of cardio-
vascular system, bones, and others should 
be monitored and, if indicated, concomitant 
medications should be administered.
 SoR: G1; QoE: +++
21. L-thyroxine treatment in other types of thyroid 
cancer.
 Patients diagnosed with MTC, poorly differentiated, 
and ATC require substitutive L-thyroxin doses only.
 SoR: G1; QoE: +++
22. Thyroid cancer in children.
 Thyroid cancer (papillary) in children and adoles-
cents commonly shows more advanced stages than 
in adults and simultaneously is characterised by 
a good prognosis, mostly if the treatment radicalness 
is sufficient. Thus, the authors of these recommen-
dations selected a Paediatric Working Group and 
prepared separate guidelines [79].
 SoR: G1; QoE: +++
23. Cancer recurrence and persistent/progressive dis-
ease.
23.1. The risk of cancer relapse in DTC is the highest 
during the first five years; however, it should 
be considered life-long, and therefore continu-
ous follow-up in a treating centre is required. 
Such follow-up should be carried out every 
5–10 years.
 SoR: G1; QoE: +++
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23.2. The optimal solution assumes the follow-up in 
the same centre where the primary treatment 
was performed.
 SoR: G1; QoE: PolCon 62/62
24. Treatment of locoregional DTC relapse.
24.1. Surgery is the main treatment option. RAI 
treatment may be administered if indicated.
 SoR: G1; QoE: +++
24.2. In the case of non-resectable tumour showing 
no RAI avidness, which demonstrates progres-
sion despite previous treatment, radiotherapy 
is recommended [63].
 SoR: G1; QoE: ++
25. Treatment of distant metastases.
25.1. RAI treatment is indicated if all metastatic le-
sions demonstrate RAI avidness.
 SoR: G1; QoE: +++
25.2. In the case of a single metastasis, surgery 
should be considered if its resection is possible 
and other metastases are excluded with a high 
probability [80].
 SoR: G1; QoE: ++
25.2.1. In a single brain metastasis the deci-
sion regarding the operation should be 
personalised, because in the case of dif-
ficult surgical approach, RAI treatment 
(if a lesion shows RAI uptake) may be 
more beneficial. Considering this issue, 
the authors’ opinion is in contrast to the 
European consensus that recommends 
neurosurgery first.
 SoR: G2; QoE: +
25.3. Induction of RAI avidness with the use of 
cis-retinoid acid is not an approved treatment 
method and should not be used outside clini-
cal trials [81].
 SoR: G1; QoE: +
26. Radiotherapy is used in the palliative treatment of 
metastases [63].
 SoR: G1; QoE: +++
27. Pharmacological treatment of DTC.
27.1. L-thyroxine administration is a hormonal 
therapy of DTC (see par. 18–20).
 SoR: G1; QoE: +++
27.2. There is no proof supporting the use of chemo-
therapy in DTC.
 SoR: G1; QoE: +
27.3. Targeted therapy with the use of tyrosine 
kinase inhibitors is recommended in DTC pa-
tients with locally advanced or disseminated 
cancer, RAI resistant, demonstrating progres-
sion fulfilling Response Evaluation Criteria 
in Solid Tumours (RECIST), version 1.1. This 
therapy is approved in the EU but not reim-
bursed in Poland [82].
 SoR: G1; QoE: +++
27.3.1. If there is no possibility to use sorafenib 
or lenvatinib, it is recommended that the 
patients are treated under randomised 
clinical trials.
 SoR: G1; QoE: +++
27.3.2. Sorafenib 400 mg BID [83].
 SoR: G1; QoE: +++
27.3.3. Lenvatinib 24 mg QID [84].
 SoR: G1; QoE: +++
27.3.4. This treatment should be carried out in 
centres experienced in targeted therapy 
and follow-up of treatment-related 
side-effects.
 SoR: G1; PolCon: 62/62
28. Medullary thyroid carcinoma.
28.1. Management in medullary thyroid cancer is 
substantially different from that of DTC, for 
the following reasons.
28.1.1. In a high percentage of cases, it is 
a hereditary disease. Using DNA analy-
sis a genetic predisposition in family 
members may be stated, in which case 
prophylactic surgery is necessary [85].
 SoR: G1; QoE: +++
28.1.2. The high specificity and sensitivity of 
serum calcitonin (Ct) evaluation justi-
fies application of this marker in MTC 
diagnosis, determination of the extent of 
surgery, early detection of MTC relapse/
progression, and its prognosis [6].
 SoR: G1; QoE: +++
28.1.3. Compared to DTC, more extensive 
elective lymphadenectomy is recom-
mended, depending on serum Ct con-
centration [86].
 SoR: G1; QoE: +++
28.1.4. High risk of pheochromocytoma in 
patients with hereditary MTC.
 SoR: G1; QoE: +++
28.1.5. Different indications and other types of 
radioisotope treatment.
 SoR: G1; QoE: +++
29. Diagnosis of MTC.
29.1. Diagnosis of MTC by FNAB is often difficult 
because it requires immunocytochemistry with 
the use of anti-Ct antibodies or confirmation 
of serum calcitonin increase.
 SoR: G1; QoE: +++
29.2. Diagnosis of MTC may be based on serum Ct 
evaluation, and if serum Ct level exceeds > 100 
pg/mL, it is highly probable [87].
 SoR: G1; QoE: +++
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29.3. The Ct stimulation test helps in resolving 
doubtful cases and improves the effectiveness 
of preoperative diagnostics and follow-up of 
MTC [88].
 SoR: G1; QoE: +++
29.4. Measurement of Ct concentration in the needle 
washout improves FNAB accuracy in MTC 
diagnosis.
 SoR: G1; QoE: +++
30. DNA tests in MTC.
30.1. A DNA test should be performed in every 
patient diagnosed with MTC, even if family 
history and physical examination do not indi-
cate hereditary MTC [89].
 SoR: G1; QoE: +++
30.2. Interpretation of DNA test with respect to 
probability of mutation carriage.
30.2.1. The DNA test is based on analysis of 
known RET proto-oncogene mutations 
in a sample of the patient’s peripheral 
blood. It should be performed in ac-
credited centres only [85].
 SoR: G1; QoE: +++
30.2.2. A negative result of full DNA analysis 
excludes hereditary MTC with a prob-
ability of 95%.
 SoR: G1; QoE: +++
30.2.3. A positive result of DNA analysis is an 
indication for testing family members 
of the patient [85].
 SoR: G1; QoE: +++
30.2.4. Detection of asymptomatic gene muta-
tion carrier and a negative DNA test in 
a family member have to be confirmed 
by a DNA test of another blood sample 
of this family member.
 SoR: G1; QoE: ++ / PolCon 62/62
30.2.5. The probability of a positive DNA result 
in a patient with a negative family his-
tory is about 10% [89].
 SoR: G1; QoE: +++
31. Management of families of RET gene mutation 
carriers.
31.1. Hereditary MTC occurs as a symptom of mul-
tiple endocrine neoplasia syndromes (MEN 
2). In typical MEN2A and MEN2B syndromes, 
MTC coexists with pheochromocytoma, its risk 
of occurrence being up to 50%. Familial MTC 
(FMTC) without other endocrinopathies is 
a variant of the MEN2A syndrome [6].
 SoR: G1; QoE: +++
31.2. In a family with hereditary MTC the risk of 
MTC in a first-degree relative is 50% [85].
 SoR: G1; QoE: ++
31.3. DNA testing to detect RET mutation carriage 
in MEN2a/FMTC families should begin at age 
of 2–3 years, and must be performed before 
five years of age [6].
 SoR: G2; QoE: ++
31.4. DNA tests in MEN2B families should be per-
formed as soon as possible, optimally within 
the first year of life [6].
 SoR: G1; QoE: +++
31.5. According to ATA MTC guidelines the follow-
ing terminology concerning RET mutations 
carriers: ATA-MOD, ATA-H, and ATA-HST is 
recommended (Table VIII).
 SoR: G2; QoE: +
32. Diagnostic management in RET mutation carriers [6].
 Complete diagnostics to evaluate current stage of 
disease, performed in RET mutation carriers, should 
involve:
 — Basal and stimulated serum Ct measure-
ment;
 — Neck ultrasound;
 — FNAB if thyroid lesions are present;
 — Abdominal ultrasound;
 — Biochemical diagnostics, to exclude pheo-
chromocytoma;
 — Serum calcium measurement.
 SoR: G1; QoE: +++
33. Total prophylactic thyroidectomy in RET mutation 
carriers.
33.1. In asymptomatic RET mutation carriers total 
prophylactic thyroidectomy should be con-
sidered [90].
 It is accepted that prophylactic surgery offers 
better protection against MTC development 
than long-term follow-up of serum Ct level.
 SoR: G1; QoE: +++
34. Total prophylactic thyroidectomy is indicated in the 
following cases [6]:
 — Right after detection of RET mutation in 
MEN2B syndrome (in this syndrome, the 
DNA test is obligatory within the first year 
of life — ATA HST category — Table VIII);
 — After the age of five years in MEN2A syn-
drome and FMTC (DNA test is performed 
between two and three years of age — ATA 
H and MOD categories).
 SoR: G2; QoE: ++
35. In carriers with RET mutations with later MTC 
onset (ATA MOD category) it is acceptable to post-
pone prophylactic surgery to above five years of 
age if the patient or parents are fully informed of 
risk related to treatment delay and fully accept this 
option, if basal serum Ct concentration is normal, 
if there are no thyroid lesions in neck ultrasound, 
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and if family history confirms a relatively mild 
course of disease.
 SoR: G2; QoE: ++ / PolCon 62/62
36. In RET mutation carriers, in whom prophylactic 
surgery has not yet been performed, stimulated 
serum Ct concentration evaluated every year may 
lead to MTC diagnosis earlier than evaluation of 
basal Ct concentration (pentagastrin is not available 
in Poland. Therefore calcium, administered intrave-
nously, is used for stimulation test).
36.1. Normal increase in serum Ct concentration 
after intravenous calcium administration does 
not exceed 30 pg/mL.
 SoR: G2; QoE: + / PolCon 62/62
36.2. An increase in serum Ct concentration above 
100 pg/mL after calcium stimulation is inter-
preted as a positive result. However, this result 
does not uniquely confirm MTC diagnosis 
(because it may result from C-cell hyperplasia). 
Nevertheless, it is an absolute indication for 
surgery in RET mutation carriers.
 SoR: G2; QoE: + / PolCon 62/62
36.3. Intravenous calcium infusion may be an alter-
native to pentagastrin test.
— Pentagastrin is not available in Poland.
 SoR: G1; QoE: ++ / PolCon 62/62
37. Diagnosis and treatment of pheochromocytoma in 
MEN2 syndrome.
37.1. Recommended diagnostic tests for pheochro-
mocytoma depend on the type of RET muta-
tion [6, 91, 92].
 SoR: G1; QoE: +++
37.2. Diagnosis of pheochromocytoma is based on 
yearly biochemical tests. In MEN2B and in 
RET codon 634 and 630 mutation carriers in 
MEN2A syndrome, these should begin at the 
age of eight years. In carriers of other types of 
RET mutation, they should begin at the age of 
20 years [6, 91].
 SoR: G1; QoE: ++
37.3. Screening abdominal CT is not necessary in 
MTC patients if there are no clinical symptoms 
of pheochromocytoma and biochemical tests 
are negative.
 SoR: G1; QoE: PolCon 62/62
37.4. Treatment of pheochromocytoma is based on 
surgery. Optimally, tumourectomy is recom-
mended [93].
 SoR: G1; QoE: ++
37.5. If pheochromocytoma and MTC coexist, adre-
nal surgery should be carried out as the first 
procedure, to avoid symptoms of excessive 
hormone secretion from this adrenal tumour.
 SoR: G1; QoE: +++
38. Surgery for pheochromocytoma.
 The operation should be preceded by at least two 
weeks of pharmacological pretreatment [93]
 SoR: G1; QoE: +++
38.1. Tumourectomy should be performed instead of 
adrenalectomy, especially if surgery concerns 
the other adrenal gland, following previous 
unilateral adrenalectomy [93].
 SoR: G1; QoE: ++
38.2. If bilateral adrenalectomy is necessary, the pa-
tient should be fully informed about the prin-
ciples of substitution therapy. IMPORTANT 
NOTICE: in hereditary MTC in the course of 
MEN2 syndrome, a significant percentage of 
deaths are related to adrenal complications — 
adrenal crisis or adrenal insufficiency.
 SoR: G1; QoE: ++
39. Diagnosis and treatment of primary hyperparathy-
roidism in the course of MEN2 syndrome.
39.1. Indications for diagnostics of primary hyper-
parathyroidism depend on the type of RET 
mutation [94].
SoR: G1; QoE: ++
39.1.1. Serum calcium evaluation once a year 
is recommended in RET codon 634 and 
RET codon 630 mutation carriers, while in 
FMTC it may be evaluated less frequently.
 SoR: G1; QoE: +++
39.1.2. The treatment of hyperparathyroidism 
in the course of MEN2A syndrome 
Table VIII. Risk classification and proposed management in RET mutations carriers regarding the type of RET mutation [6]
ATA risk category Type of RET mutation Management
ATA-HST MEN 2B / RET codon 918 Total thyroidectomy in the first year of life
Level VI lymph node dissection dependent 
on the ability to identify or preserve or 
transplant the parathyroid glands
ATA-H MEN 2A / RET codon 634 Total thyroidectomy at or before 5 years based on serum Ct levels
ATA-MOD MEN 2A / other types 
— RET  
— mutation
Total thyroidectomy to be performed when the serum Ct level becomes 
elevated or in childhood if parents do not wish to embark on lengthy 
period of evaluation
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should follow generally accepted rules. 
IMPORTANT NOTICE: Hyperparathy-
roidism is often caused by parathyroid 
hyperplasia; therefore, the risk of unsuc-
cessful surgery is higher than in the case 
of single adenoma [95].
 SoR: G2; QoE: +
40. Surgery in clinically apparent MTC.
40.1. If MTC is clinically apparent (the presence of 
a thyroid nodule and a positive result of FNAB) 
thyroid surgery should always involve total thy-
roidectomy accompanied by central neck dis-
section, both in hereditary and sporadic MTC.
 SoR: G1; QoE: +++
40.2. The extent of lateral neck lymphadenectomy 
depends on the presence of lymph node me-
tastases in neck ultrasound and on serum Ct 
concentration [49].
 SoR: G1; QoE: +++
40.3. There are no unequivocal indications for lateral 
neck lymphadenectomy if no enlarged lymph 
nodes have been found and if preoperative 
serum Ct concentration is below 200 pg/mL [49].
 SoR: G1; QoE: ++
40.4. If serum Ct concentration is above 400 pg/mL, 
the result of abdominal CT scan should be 
known to the surgeon planning the extent of 
local surgery [86].
 SoR: G1; QoE: +++
40.5. ATA MTC guidelines specify serum calcitonin 
concentration of 150 pg/mL as the lower limit 
value for these indications.
 SoR: G1; QoE: ++ 
41. Surgery in early detected MTC.
41.1. If the reason for surgery is elevated serum Ct 
concentration in a patient with nodular goitre, 
total thyroidectomy is recommended.
 SoR: G1; QoE: +++
41.2. If a small MTC lesion below 10 mm has been 
incidentally diagnosed after less than total thy-
roidectomy, and postoperative both basal and 
stimulated serum Ct concentration is within 
the normal range, genetic testing for hereditary 
mutation in the RET gene is negative, and no 
other risk factors are apparent, resignation from 
secondary total thyroidectomy is acceptable.
 SoR: G2; QoE: +
42. Prophylactic surgery in RET mutation carriers.
42.1. Indications for prophylactic thyroidectomy 
given in par. 34 should include the result of 
DNA analysis (type of RET mutation), current 
Ct concentration, patient’s age, and family 
history. In such a case thyroid cancer surgery, 
in general recommended in a specialist centre, 
should only be performed in a highly experi-
enced referral centre.
 SoR: G2; QoE: +
42.2. Prophylactic total thyroidectomy performed in 
a timely manner (see par. 34 and 35) may not 
include central neck dissection if basal serum 
Ct concentration is normal and there are no 
symptoms of nodal involvement.
 SoR: G2; QoE: ++
42.3. If at the age of five years a RET mutation 
MEN2A/FMTC predisposing a carrier shows 
no increase in basal serum Ct concentration, 
the calcium stimulation test may be useful in 
deciding whether surgery may be postponed. 
However, the type of RET mutation should 
also be considered.
 SoR: G2; QoE: + / PolCon 62/62
42.4. If prophylactic operation has not been per-
formed at the optimal age, as given in par. 36, 
and if basal serum Ct concentration is normal, 
a calcium stimulation test performed once 
a year may decrease the chance of missing the 
optimum time to perform surgery.
 SoR: G2; QoE: + / PolCon 62/62 
43. Postoperative evaluation and follow-up in MTC.
43.1. Postoperative assessment of serum Ct con-
centration.
43.1.1. Normalisation of postoperative Ct 
concentration is the best indicator of 
achieving radical surgery and is a posi-
tive prognostic factor.
 SoR: G1; QoE: +++
43.1.2. While the authors of these recommen-
dations are aware that some Ameri-
can specialists consider the calcium 
stimulation test to be unnecessary, the 
experience of many European centres 
supports calcitonin stimulation tests in 
patients with normal basal Ct concen-
tration. The negative result of calcium 
stimulation test (some authors suggest 
no increase of Ct concentration as the 
optimum response to this test) is a reli-
able prognostic factor.
 SoR: G2; QoE: + / PolCon 62/62
43.1.3. One should remember that if Ct concen-
trations above 300–500 pg/mL are stated, 
serum dilution is required in order to 
obtain a reliable result.
 SoR: G2; QoE: + / PolCon 62/62
43.1.4. Estimation of serum Ct doubling time 
is recommended because it is of proven 
prognostic and predictive value.
 SoR: G1; QoE: + / PolCon 62/62
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43.2. Further MTC follow-up involves:
 — serum Ct evaluation;
 — neck ultrasound;
 — serum CEA concentration;
 — imaging tests — only if serum Ct concentra-
tion exceeds 150 pg/mL or rather 400 pg/mL.
 SoR: G1; QoE: ++ / PolCon 62/62
43.3. Management in the case of asymptomatic 
increase in serum Ct concentration.
 Ct concentration is a very sensitive marker of 
tumour mass.
 SoR: G1; QoE: +++
43.3.1. At Ct concentration below 150 pg/mL, 
imaging tests such as CT, MRI, or PET/
CT are not justified as they are not able 
to detect cancer foci.
 SoR: G1; QoE: ++ 
43.3.2. At Ct concentration range 150–1000 pg/
mL, a possible false negative result in 
the localisation of cancer foci by imaging 
tests should be considered.
 SoR: G1; QoE: +++
43.3.3. If Ct concentration ranges between 400 
and 1000 pg/mL the possibility of cancer 
foci localisation increases [96].
 SoR: G1; QoE: +++
43.3.4. At asymptomatic increase of Ct concen-
tration, central neck dissection (if not 
previously performed) and/or elective 
lateral neck lymphadenectomy may be 
considered.
 SoR: G2; QoE: ++
43.3.5. IMPORTANT NOTICE: liver microme-
tastases may often be the reason for 
increased serum Ct concentration.
 SoR: G1; QoE: +++
44. Management in recurrent MTC.
44.1. Surgery is the basic treatment of local and 
locoregional recurrence.
 SoR: G1; QoE: +++
44.2. If local/locoregional recurrence is accompanied 
by distant metastases, the indications for neck/
mediastinal surgery are equivocal.
 SoR: G2; QoE: +
44.3. Disseminated MTC very rarely involves a single 
metastatic lesion; therefore, surgical treatment 
of metastatic disease, particularly of liver me-
tastases, is generally not justified.
 SoR: G2; QoE: + / PolCon 62/62
44.4. Adjuvant teleradiotherapy is indicated only in 
the case of non-radical surgery at the micro- or 
macroscopic level. Palliative teleradiotherapy is 
often used in bone and brain metastases, and 
rarely in other metastatic locations.
 SoR: G2; QoE: +
44.5. Classical chemotherapy it is not recommended.
 SoR: G1; QoE: +++
44.6. Isotope therapy with different radiopharma-
ceuticals selectively taken up by cancer cells is 
usually a palliative treatment.
 SoR: G1; QoE: +++
44.7. The effectiveness of somatostatin analogues in 
MTC stabilisation has not been demonstrated.
 SoR: G1; QoE: +++
44.8. Targeted therapy with the use of tyrosine kinase 
inhibitors is recommended in MTC patients 
with locally advanced or disseminated cancer, 
demonstrating progression fulfilling RECIST 
1.1 criteria. This therapy is approved in the EU 
but not reimbursed in Poland (June 2017) [97].
44.8.1. If use of vandetanib or cabozantinib is 
not possible, treatment of the patients 
under randomised clinical trials is rec-
ommended.
 SoR: G1; QoE: +++ / PolCon 62/62
44.8.2. Vandetanib — 300 mg once a day [98]
SoR: G1; QoE: +++
44.8.3. Cabozantinib — 140 mg once a day [99].
 SoR: G1; QoE: +++
45. Treatment of poorly differentiated and undifferenti-
ated (anaplastic) thyroid cancer.
45.1. The prognosis in anaplastic thyroid carcinoma 
is poor. Radical surgery or radical radiotherapy 
are rarely possible and results of chemotherapy 
are disappointing [100, 101].
 SoR: G1; QoE: +++
45.2. Pharmacological treatment.
45.2.1. Chemotherapy is based on doxorubicin 
or on multidrug regimens. However, 
the superiority of the latter has not 
been proven. Concomitant radio- and 
chemotherapy is still at the stage of 
experimental therapy.
 SoR: G1; QoE: +++
45.2.2. New schemes of chemotherapy and tar-
geted therapy should be applied within 
clinical trials.
 SoR: G1; QoE: PolCon 62/62
46. Diagnostics and treatment of primary thyroid 
lymphoma.
46.1. In the diagnostics of primary MALT thyroid 
lymphoma, imaging tests including ultra-
sound, CT, or MRI are necessary to exclude 
thyroid involvement in the course of dissemi-
nated lymphoma [102].
 SoR: G1; QoE: +++
46.2. Indications for surgery in primary thyroid 
lymphoma are not unequivocal, and surgery 
does not improve the long-term outcome.
 SoR: G1; QoE: ++
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46.3. Radio- and chemotherapy are often the main 
treatment and their postoperative indication 
depends on tumour grade and advancement.
 SoR: G1; QoE: +++
47.  Rehabilitation, psychological care, and psycho-
therapy.
 Adequate emotional and social support should be 
provided for patients with thyroid cancer, during 
and after completion of their oncological therapy, in-
cluding full psychosocial recovery. Centres in which 
thyroid cancer is treated should offer specialised 
psycho-oncological and psychiatric care whenever 
necessary. Development of psychotherapy pro-
grammes aimed at rehabilitation and full return to 
the social roles held by patients prior to their treat-
ment, is recommended. 
 SoR: G1; QoE: PolCon 62/62
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